Clinical trial NCT04270942
Conditions: Diabetes Mellitus, Type 1
Keywords: Recent-onset type 1 diabetes Teplizumab T1D Stage 3 Type 1 diabetes New onset type 1 diabetes
Sponsor: Provention Bio, a Sanofi Company
Start date: 2020-02-26; Completion date: 2024-01-22
Enrollment: 6 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
This study was an extension of the NIH-sponsored At-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who developed clinical type 1 diabetes after the conclusion of that trial, were eligible to enroll and receive teplizumab treatment within one year of diagnosis of clinical type 1 diabetes.

Detailed description:
The study was a single-arm, multicenter, open-label clinical trial. All participants received a 12-day course of teplizumab given through daily IV infusion and were followed for 78 weeks.

The purpose of this study was to evaluate the safety and tolerability of teplizumab treatment, administered intravenously (IV) to participants in the NIH-sponsored trial who have developed type 1 diabetes and were able to start teplizumab treatment within 1 year of diagnosis of type 1 diabetes. Whether teplizumab treatment reduced the loss of insulin-producing pancreatic beta cells were evaluated.

Arms: arm 1: Administration of teplizumab by intravenous infusion for 12 consecutive days
Interventions: intervention 1: teplizumab 1 mg/mL
Intervention descriptions: intervention 1: Solution for infusion administered as IV infusion (anti-CD3 humanized monoclonal antibody).

Cumulative dose: 9 mg/m2. Day 1: 106 μg/m2, Day 2: 425 μg/m2, Days 3-12: 850 μg/m2 daily

Protocol documents:
Prot_000.pdf: 
CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
1 
Clinical Protocol 
Protocol Title: 
An Open-Label Study to Evaluate the Safety of Teplizumab 
(PRV-031) in At-Risk Relatives Who Develop Type 1 Diabetes 
Protocol Number: 
PRV-031-002 
Version Number: 
1.0 
Compound:   
Teplizumab 
Study Phase:   
2 
Short Title:   
At-Risk Extension 
Sponsor Name:  
Provention Bio, Inc. 
Legal Registered Address: 
P.O. Box 666 
Oldwick, NJ 08858 
Regulatory Agency Identifier Number(s): 
IND: 102,629 
EudraCT:  TBD 
NCT: NCT04270942 
Approval Date: 
02 December 2019 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
2 
DOCUMENT HISTORY 
Document 
Date 
Original Protocol (version 1.0) 
02-Dec-2019
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
3 
Table of Contents 
1.
Protocol Summary ..........................................................................................................6 
1.1. 
Synopsis ............................................................................................................................6 
1.2. 
Schema ..............................................................................................................................7 
1.3. 
Schedule of Events............................................................................................................8 
2.
Introduction ...................................................................................................................10
2.1. 
Type 1 Diabetes (T1D) ...................................................................................................10 
2.1.1. 
Definition and metabolic characteristics of Type 1 diabetes 
mellitus ............................................................................................................................10 
2.1.2. 
Natural History of Type 1 Diabetes ................................................................................10 
2.2. 
Teplizumab Overview.....................................................................................................11 
2.2.1. 
Results from the TN-10 Study ........................................................................................12 
2.3. 
Safety Experience with Teplizumab ...............................................................................14 
2.4. 
Use of Teplizumab in Children .......................................................................................17 
2.5. 
Benefit/Risk Assessment ................................................................................................18 
3.
Objectives and Endpoints ............................................................................................19 
4.
Study Design ..................................................................................................................20 
4.1. 
Overall Design ................................................................................................................20 
4.2. 
Scientific Rationale for Study Design ............................................................................20 
4.3. 
Justification for Dose ......................................................................................................21 
4.4. 
End of Study Definition ..................................................................................................23 
5.
Study Population ...........................................................................................................24 
5.1. 
Inclusion Criteria ............................................................................................................24 
5.2. 
Exclusion Criteria ...........................................................................................................24 
5.3. 
Enrollment ......................................................................................................................25 
6.
Study Drug Dosing ........................................................................................................26 
6.1. 
Study Drug Administered ...............................................................................................26 
6.2. 
Preparation/Handling/Storage/Accountability ................................................................26 
6.3. 
Concomitant Therapy .....................................................................................................27 
6.3.1. 
Diabetes Management and Insulin Use ...........................................................................27 
6.3.2. 
Prophylactic Medications................................................................................................27 
6.3.3. 
Prohibited Medications ...................................................................................................28 
6.3.4. 
Emergency Precautions ...................................................................................................28 
7.
Interruption or Discontinuation of Study Drug Treatment
and Participant Discontinuation/Withdrawal ............................................................30 
7.1. 
Interruption of Study Drug Treatment ............................................................................30 
7.2. 
Discontinuation of Study Drug Treatment......................................................................31 
7.3. 
Participant Discontinuation/Withdrawal from the Study ................................................32 
7.4. 
Lost to Follow-up............................................................................................................33 
8.
Study Assessments and Procedures.............................................................................34 
8.1. 
Screening and Baseline Assessments .............................................................................34 
8.1.1. 
Screening (Visit -1) .........................................................................................................34 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
4 
8.1.2. 
Baseline Assessments and Initiation of Teplizumab Treatment 
(Visit 1) ...........................................................................................................................34 
8.2. 
Post-Baseline Visits ........................................................................................................34 
8.3. 
Efficacy Assessments .....................................................................................................35 
8.3.1. 
Metabolic Assessments ...................................................................................................35 
8.3.2. 
Mechanistic Outcome Assessments ................................................................................35 
8.4. 
Safety Assessments .........................................................................................................36 
8.4.1. 
Adverse Events and Serious Adverse Events .................................................................36 
8.4.2. 
Clinical Safety Laboratory Assessments ........................................................................37 
8.4.3. 
Physical Examinations ....................................................................................................38 
8.4.4. 
Vital Signs and Infusion Reaction Monitoring ...............................................................38 
8.4.5. 
Pregnancy ........................................................................................................................38 
8.5. 
Pharmacokinetics and Immunogenicity ..........................................................................39 
8.6. 
Pharmacodynamics .........................................................................................................39 
8.7. 
Genetics ..........................................................................................................................39 
9.
Statistical Considerations .............................................................................................40 
9.1. 
Statistical Hypotheses .....................................................................................................40 
9.2. 
Sample Size Determination ............................................................................................40 
9.3. 
Populations for Analyses ................................................................................................40 
9.4. 
Statistical Analyses .........................................................................................................40 
9.4.1. 
Primary Endpoint: Safety ................................................................................................40 
9.4.2. 
Secondary Endpoints ......................................................................................................40 
9.4.3. 
Handling Missing/Discontinued Participants .................................................................41 
9.5. 
Interim Analyses .............................................................................................................41 
10.
Supporting Documentation and Operational Considerations ..................................42 
10.1. 
Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations ................................................................................................................42 
10.1.1. Study-Specific Design Considerations ...........................................................................42 
10.1.2. Investigator Responsibilities ...........................................................................................42 
10.1.3. Regulatory and Ethical Considerations ...........................................................................42 
10.1.4. Informed Consent Process ..............................................................................................43 
10.1.5. Data Protection................................................................................................................44 
10.1.6. Registration of Clinical Studies and Disclosure of Results ............................................47 
10.1.7. Required Pre-study Documentation ................................................................................47 
10.1.8. Monitoring ......................................................................................................................48 
10.1.9. Data Quality Assurance ..................................................................................................48 
10.1.10. Source Documentation ....................................................................................................49 
10.1.11. Case Report Form Completion .......................................................................................49 
10.1.12. Record Retention ............................................................................................................50 
10.1.13. Study Completion/Termination ......................................................................................50 
10.1.14. Study Completion/End of Study .....................................................................................50 
10.1.15. Study Termination ..........................................................................................................51 
10.1.16. On-Site Audits ................................................................................................................51 
10.2. 
Appendix 2: Clinical Laboratory Tests Performed Locally ............................................52 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
5 
10.3. 
Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow-up, and Reporting .........................................................53 
10.3.1. Definition of AE .............................................................................................................53 
10.3.2. Definition of SAE ...........................................................................................................54 
10.3.3. Definition of AESI ..........................................................................................................55 
10.3.4. Reporting and Follow-Up of AE and/or SAE .................................................................56 
10.4. 
Appendix 4: Contraceptive Guidance and Collection of 
Pregnancy Information ...................................................................................................59 
10.5. 
Appendix 5: Abbreviations .............................................................................................61 
11.
References ......................................................................................................................64
In-Text Tables 
Table 1: Grade of adverse events related to study drug ................................................................ 15 
Table 2: Adverse events by category and designated and possibly, probably, or definitely related 
to study drug. ................................................................................................................................ 16 
In-Text Figures 
Figure 1: Effects of Teplizumab Treatment on Development of Type 1 Diabetes ....................... 13 
Figure 2: Percentage of KLRG1+TIGIT+CD8+ of total CD3+ T cells in the teplizumab and 
placebo treated participants........................................................................................................... 14 
Figure 3: Absolute lymphocyte counts in the study groups are shown over the first 7 weeks after 
enrollment ..................................................................................................................................... 17 
Figure 4: PK Simulation of 12-Day and 14-Day Dosing Regimens ............................................. 22 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
6 
1.
Protocol Summary
1.1. 
Synopsis
Protocol Title:  An Open-Label Study to Evaluate the Safety of Teplizumab (PRV-031) in At-
Risk Relatives Who Develop Type 1 Diabetes 
Short Title: At-Risk Treatment Protocol 
Rationale: 
Teplizumab (also known as PRV-031, hOKT3γ1 [Ala-Ala], and MGA031) is a humanized 150-
kilodalton monoclonal antibody (mAb) that binds to the CD3-ε epitope of the T cell receptor. A 
recently completed TrialNet study (TN-10) demonstrated that teplizumab significantly delayed the 
onset of clinical diabetes in relatives at very high risk for type 1 diabetes (T1D). As teplizumab is 
predicted to preserve beta cell function, participants who were in the TN-10 trial and have 
subsequently developed clinical T1D after the conclusion of that trial, are eligible to enroll and 
receive teplizumab treatment in this open-label study within one year of their clinical T1D 
diagnosis.  
Objectives and Endpoints 
Objectives 
Endpoints 
Primary 
•
To evaluate the safety and tolerability
of teplizumab treatment, administered
intravenously (IV) to participants in
the TN-10 trial who have developed
T1D.
•
Incidence of treatment-emergent
adverse events (TEAEs), adverse
events of special interest (AESIs), and
serious adverse events (SAEs)
Secondary 
•
To evaluate the pharmacokinetics
(PK) and immunogenicity of
teplizumab
•
To evaluate whether teplizumab
treatment reduces the loss of β cells,
over 78 weeks (18 months), in
individuals with recent diagnosis of
T1D.
•
To evaluate key clinical parameters of
diabetes management, including
insulin use, hemoglobin A1c (HbA1c),
and clinically important hypoglycemic
episodes over 78 weeks
•
Levels of teplizumab in the serum and
anti-drug antibodies
•
The area under the time-versus-
concentration curve (AUC) of
C-peptide after a 4-hour (4h) mixed-
meal tolerance test (MMTT), a
measure of endogenous insulin
production and β cell function, over
78 weeks
•
HbA1c levels; insulin use, defined as
a daily average dose in units per
kilogram per day (U/kg/day); and
frequency of clinically important
hypoglycemic episodes over 78 weeks
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
7 
Objectives 
Endpoints 
• To evaluate whether treatment with 
teplizumab increases the frequency of 
exhausted T cells  
• Frequency of CD8+ TIGIT+ KLRG1+ 
T cells 
 
Overall Design 
The study is a single-arm, multicenter, open-label clinical trial.  
Teplizumab-treated and placebo participants who were in the TrialNet TN-10 trial, have been 
diagnosed with T1D, and are able to start teplizumab treatment within 1 year of the T1D diagnosis 
are eligible to enroll in this open-label study.  
Number of Participants: 
Up to 30 participants may be enrolled in this study. 
Treatment and Study Duration: 
All participants will receive a 12-day course of teplizumab given through daily IV infusion.  
Participants will have a screening period of up to 4 weeks, a treatment period of 12 days, and a 
follow-up period of up to 78 weeks (18 months) from the first dose of treatment.  
1.2. 
Schema 
The study schema is noted below. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 8 
1.3. 
Schedule of Events 
Week 
-4 
1 
2 
4 
12 
26 
52 
78 
ET 
Month 
-1
1 
3 
6 
12 
18 
ET 
Day 
Screen1
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
28 
84 
182 
364 
546 
ET 
Visit window 
Not applicable 
±4 
days 
±4 
days 
±2 
wks 
±2 
wks 
±2 
wks 
Visit number 
-1
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
ET 
Informed consent/assent 
X 
Inclusion/exclusion criteria review 
X 
X 
Medical history 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Height (cm) & weight (kg) 
X 
X 
X 
X 
X 
Vital signs2 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical exam (C=Complete; 
P=Partial) 
C 
P 
P 
P 
P 
P 
P 
C 
Previous/concomitant medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse event review 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Teplizumab dose calculation 
X 
Premedication 
X 
X 
X 
X 
X 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
Teplizumab administration4 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Tuberculosis testing (PPD or IGRA) 
X 
Chemistry and LFTs5,6 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
CBC with differential and platelets5 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Teplizumab levels7 
X 
X 
X 
X 
X 
X 
X 
X 
Anti-teplizumab antibodies7 
X 
X 
X 
X 
X 
X 
X 
X 
EBV/CMV serology8 
X 
EBV and CMV viral loads8 
X 
X 
X 
HIV, HBV, HCV serology8 
X 
4h MMTT9 
X 
X 
X 
X 
X 
T1D autoantibodies 
X 
Urine pregnancy test (WOCBP only) 
X 
X 
X 
X 
X 
X 
X 
X 
Urine ketones10 
HbA1c 
X 
X 
X 
X 
X 
X 
Mechanistic assessments11 
X 
X 
X 
X 
X 
X 
X 
X 
Abbreviations: ALT=alanine aminotransferase, AST=aspartate aminotransferase, BP=blood pressure, BUN=blood urea nitrogen, CBC=complete blood count, 
CMV=cytomegalovirus, EBV=Epstein-Barr virus, EBNA=Epstein-Barr nuclear antigen, ET=early termination visit, HbA1c=hemoglobin A1c, HBV=hepatitis B virus, 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 9 
HCV=hepatitis C virus, HIV=human immunodeficiency virus, Ig=immunoglobulin IGRA= interferon-gamma release assay, LDH=lactate dehydrogenase, MMTT= mixed-meal 
tolerance test, PPD=purified protein derivative, T1D=type 1 diabetes, WOCBP=women of childbearing potential 
Footnotes: 
1.
Enrollment must occur within 4 weeks of screening.
2.
Vital signs include temperature, pulse, blood pressure, and respiration. On dosing days, vital signs should be collected pre-dose, 15 minutes after the start of infusion, at the
end of infusion, and 60 minutes after the end of infusion.
3.
Pre-treatment medications are required on Days 1-5, optional on Days 6-12.
4.
Teplizumab dose: Day 1: 106 μg/m2, Day 2: 425 μg/m2, Days 3 to 12: 850 μg/m2 daily.
5.
These results must be reviewed prior to drug administration (see Section 8.1.2). CBC with differentials are done locally.
6.
Liver function tests (ALT, AST, LDH, alkaline phosphatase, total protein, albumin, total and direct bilirubin) and chemistries (sodium, potassium, chloride, CO2, glucose,
BUN, creatine) are done locally. Day 1 samples should be obtained pre-dose.
7.
Blood samples for the measurements of teplizumab trough levels and anti-drug antibodies are to be obtained within 30 minutes before study drug infusion.
8.
Serology assessments include EBV IgG and IgM, EBNA, CMV IgG and IgM, HIV, HBV, and HCV are done locally. All participants, regardless of whether they are
seropositive or seronegative for EBV and CMV at screening, will be tested for viral load by the central lab at the indicated visits.
9.
MMTT: 4-hour samples should be collected pre-dose on Day 1. Samples will be archived for possible future pro-insulin analysis.
10. In participants who have discontinued insulin therapy, urine ketones should be checked once daily.
11. Includes samples for RNA, plasma, serum, DNA, and measurements of B and T cell numbers and function to understand the effect of therapy on the immune system and
infectious disease. Day 1 samples should be obtained pre-dose.
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 10 
2.
Introduction
2.1. 
Type 1 Diabetes (T1D) 
2.1.1. 
Definition and metabolic characteristics of Type 1 diabetes mellitus 
Type 1 diabetes mellitus (T1D) is an immune-mediated disease in which insulin-producing beta 
cells are completely or near completely destroyed, resulting in life-long dependence on exogenous 
insulin.  It is a chronic and potentially disabling disease that represents a major public health and 
clinical concern.  The number of patients being diagnosed with type 1 diabetes is increasing each 
year and is approaching an epidemic level in some countries that track this information 
(Imperatore 2018, EURODIAB 2000). 
Compared to individuals with the more common form of diabetes, Type 2 diabetes, the metabolic 
impairment in T1D is much more severe and the loss of insulin production more complete. 
Continuous exogenous insulin therapy is needed to prevent ketoacidosis and allow assimilation of 
food and to maintain life. Most likely as a consequence of the absolute deficiency of insulin, 
glucose counter regulation (i.e. the hormonal response to insulin induced hypoglycemia) is 
impaired, and therefore, hypoglycemia is a frequent complication of the disease. The occurrence 
of hypoglycemia limits the ability to achieve near normal glucose control. The Diabetes Control 
and Complications Trial (DCCT) showed that the long-term complications could be reduced with 
near normal control of glucose levels but at the cost of an increased frequency of 
severe hypoglycemia (DCCT 1993). While there have been significant improvements in insulin 
delivery systems, such as continuous subcutaneous insulin infusions with insulin pumps, 
normal glucose control, particularly in children, is rarely achieved. Individuals with Type 1 
diabetes remain at risk for secondary end-organ complications including visual impairment and 
blindness, renal failure, vascular disease and limb amputation, peripheral neuropathy, 
stroke, acute risk for severe hypoglycemia, and others. Moreover, at the time of diagnosis, 
many individuals, and children in particular, 
suffer 
significant 
morbidity 
frequently 
requiring 
intensive 
care 
admission. Contemporary clinical data support the need for 
prevention of T1D: two recent studies identified loss of 17.7 and 14.2 life-years among men 
and women, respectively, who were diagnosed as children before age 10, and 11 and 13 life-
years lost for Scottish men and women diagnosed before age 20 (Livingstone 2015, Rawshani 
2018). Prevention of T1D remains, therefore, an important unmet medical need.   
2.1.2. 
Natural History of Type 1 Diabetes 
Much is known about the natural history of the T1D disease process (Atkinson 2005). Although 
all people are susceptible, relatives of individuals with T1D are at much greater risk for 
development of the disease.  In the general population, approximately 0.3 % of individuals will 
develop T1D. In contrast, those with a relative with T1D have a 5% incidence of disease – a 15-
fold increase (Riley 1990).  Further risk stratification among family members depends upon 
genetic, immune and metabolic data (Sherr 2008).   
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 11 
In genetically susceptible persons, T1D progresses through asymptomatic stages prior to the 
development of overt hyperglycemia. These stages are characterized by the appearance of 
autoantibodies (Stage 1) and then dysglycemia (Stage 2). In Stage 2, metabolic responses to a 
glucose load are impaired but other metabolic indices, for example, glycosylated hemoglobin, 
remain normal, and insulin treatment is not needed (Riley 1990). These immunologic and 
metabolic features can identify persons at high-risk for development of clinical disease; overt 
hyperglycemia, once it develops (Stage 3), requires insulin treatment.  
Based on data from the Diabetes Prevention Trial, type 1 diabetes (DPT-1) and other natural 
history studies, the risk for developing diabetes in relatives without the disease can be defined by 
the presence of autoantibodies and the degree of metabolic impairment (Sosenko 2006).  
Autoantibody positive subjects enrolled in the DPT-1 study who had impaired or indeterminate 
glucose tolerance (ie, a glucose level after ingestion of oral glucose of > 200 mg/dL before 
120 min, and/or a glucose level at 120min 140-200 mg/dL and/or fasting glucose between 110 and 
126 mg/dL) were at very high risk (78% over 5 years) of developing T1D over a follow-up period 
of 5 to 6 years. Similar results confirming the very high risk of those with abnormal glucose were 
found in the ENDIT (European Nicotinamide Diabetes Intervention Trial) study in 
which nicotinamide failed to prevent the onset of diabetes in relatives at risk for the disease 
(Gale 2004). The results of the recently completed study, “Anti-CD3 Monoclonal Antibody 
(Teplizumab) for Prevention of Diabetes in Relatives At-Risk for Type 1 Diabetes 
Mellitus” (TrialNet TN-10) confirmed this high risk: The median time to diagnosis of T1D in 
the high-risk group with these clinical features was 24.4 months. In the TN-10 study there was 
a decline in the ability to make insulin in the placebo-treated participants. The mean (standard 
deviation [SD]) decline in the insulin secretory capacity (calculated from a 2-compartment 
model and adjusted for age and body surface area) was 44061±253 (SD) pmol/ml/120 min 
(n=30).  
2.2. 
Teplizumab Overview 
The Fc-engineered teplizumab [hOKT3γ1 (Ala-Ala)] was developed as an approach to mitigate 
the adverse effects of OKT®3 resulting from Fc/FcR engagement (Keymeulen 2005).  OKT®3 
produces profound, transient T-cell depletion in vivo.  It also activates T cells, is strongly 
mitogenic, and its use in vivo is associated with severe cytokine-release syndrome (incidence 
>90%).  The cytokine-release syndrome (CRS) induced by OKT®3 is characterized by fever,
chills, nausea, vomiting and other symptoms, and usually requires corticosteroid therapy to
suppress.  OKT®3 also is associated with a small incidence of EBV lymphomas (~1%-2%).  T-
cell activation is strongly facilitated by the interaction of Fc component of OKT®3 with Fc
receptors on lymphocytes (Fc/FcR engagement).
Teplizumab is a 150-KD humanized mAb that binds the CD3-e epitope of the T cell receptor 
(TCR) complex with affinity equal to OKT®3, but it differs from OKT®3 in two properties: 
1. The humanization process has resulted in the generation of a mAb that used less than 10%
of the original murine amino acids in the antibody construction.  The clinical consequence
of this property is reduced immunogenicity or formation of anti-idiotypic antibodies.
2. Two amino acids have been changed (leucine234 to an alanine and leucine 235 to an
alanine) in the Fc portion of the immunoglobulin that disrupt Fc receptor and complement
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 12 
component C1q binding.  These two amino acid changes were aimed at eliminating the 
majority of cytokine-mediated toxicity observed during infusions of OKT®3.  
The modified Fc component of teplizumab minimizes the activating capacity of the antibody 
compared with unmodified murine OKT®3.  
Teplizumab has been evaluated in a number of clinical trials in the prevention or delay of T1D in 
high risk individuals and in new onset T1D, as well as in renal and islet allo-transplantation, and 
psoriatic arthritis. There are ongoing studies evaluating teplizumab in newly-diagnosed pediatric 
patients (Phase 3 PROTECT study, PRV-031-001) and in combination therapy with a genetically 
modified strain of Lactobacillus designed to secrete human pro-insulin and human interleukin-10. 
By far the most extensive clinical trial experience is in children and adults with newly diagnosed 
T1D, where over 1000 individuals in 7 studies have been treated with teplizumab. Results from 
these studies suggest that it is a promising candidate for disease modification of T1D. In pilot and 
proof-of-concept clinical studies conducted in young children, adolescents, and adults, short 
courses (approximately 2 weeks) of teplizumab treatment have been shown to be safe and well 
tolerated, resulting in relative sparing of β cell function in those who were recently diagnosed 
with T1D (Herold 2002, Herold 2005, Herold 2013a, Herold 2013b). 
A multi-arm, multinational Phase 2/3 study of teplizumab (known as the “Protégé” study) was 
previously conducted by MacroGenics and Eli Lilly and Company. Over 500 children and adults 
8 to 35 years old with T1D were enrolled within 12 weeks of diagnosis and evaluated in 3 
different teplizumab dosing regimens or placebo (Sherry 2011, Hagopian 2013). The study used 
a novel and untested composite primary endpoint integrating glycemic control, measured by 
hemoglobin A1c (HbA1c) level, and insulin use; specifically, participants were considered to 
meet the primary endpoint if they had HbA1c <6.5% and insulin use <0.5 units/kg/day at 1-year 
post randomization. Although the study did not meet this primary endpoint, the study results in 
the randomized treatment group (14-day regimen, 9 mg/m2 dose per course) showed a 
statistically significant benefit in slowing the decline in C-peptide at 18 and 24 months, which 
supported the findings of previous studies that teplizumab does have the ability to preserve β cell 
function in those newly diagnosed with T1D (Hagopian 2013). Furthermore, the effect of 
teplizumab treatment was even more notable in participants with the following characteristics at 
the time of study entry: enrolled in sites in the United States, 8 to 17 years of age, higher baseline 
C peptide levels, and randomized within 6 weeks of TID diagnosis (Hagopian 2013). 
2.2.1. 
Results from the TN-10 Study 
The recently completed TN-10 study “Anti-CD3 mAb (teplizumab) for Prevention of Diabetes in 
Relatives At-Risk for Type 1 Diabetes Mellitus” study (referred to as TN-10 hereafter) tested 
whether a single 14-day course of treatment with teplizumab would delay the time to diagnosis of 
T1D in relatives of patients with T1D who were at very high risk for the diagnosis based on the 
criteria of at least 2 autoantibodies and dysglycemia during an oral glucose tolerance test (Herold 
2019). Participants were randomized to a single 14-day course of teplizumab or placebo and 
followed for development of type 1 diabetes using oral glucose tolerance tests performed at 6-
month intervals. Seventy-six participants (55/76 [72%] were less than 18 years of age) were 
randomized (44 to teplizumab; 32 to placebo). Median follow-up was 745 days (range 74-2683 
days). The duration of follow up was more than three years in 57 (75%) participants. Type 1 
diabetes was diagnosed in 42 (55%) participants.  
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 13 
The primary endpoint was the time to the diagnosis of T1D, which occurred in 19 (43%) 
teplizumab and 23 (72%) of placebo participants.  The hazard ratio of teplizumab to placebo was 
0.412 (95% CI: 0.216, 0.783, adjusted Cox proportional hazards, p=0.006) (Figure 1). The 
annualized rates of diabetes were 14.9% and 35.9% per year, in the teplizumab and placebo arms, 
respectively. 
Figure 1: Effects of Teplizumab Treatment on Development of Type 1 Diabetes 
Although the primary mechanism of action of the antibody involves binding the CD3 antigen target 
on T cells, recent studies have suggested that the mode of action of teplizumab involves induction 
of CD8+ T cells characterized by the expression of EOMES, TIGIT, and KLRG1. These cells were 
originally identified by a RNAseq analysis of peripheral blood cells and confirmed by 
flow cytometry in the clinical responders (Long 2016). In the TN-10 study, an increase in the 
frequency of the TIGIT+KLRG1+ CD8+ T cells (of the CD3+ cells) in the teplizumab-treated 
subjects at 3 and 6 months after enrollment was observed compared to baseline and compared to 
placebo treated participants (Figure 2). 
Kaplan-Meier estimates of the proportion 
of participants who had not developed 
clinical diabetes in the two study arms. The 
overall hazard ratio was 0.412 (95% CI: 
0.216, 0.783) (p=0.006, two-sided, Cox 
model). The median time to type 1 diabetes 
was 48.4 months for teplizumab group and 
24.4 months for the placebo group. The 
insert 
shows 
the 
total 
number 
of 
participants with and without clinical type 
1 diabetes at the conclusion of the study.  
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 14 
Figure 2: Percentage of KLRG1+TIGIT+CD8+ of total CD3+ T cells in the teplizumab and 
placebo treated participants. 
Studies from other clinical settings suggest that these cells have impaired function (i.e. 
“exhaustion”). It is postulated that cells with this phenotype are unable to cause the autoimmune 
killing of insulin producing beta cells that is the hallmark of the disease. These CD8+ T cells are 
not, however, inactive, since, in the TN-10 study, the few persons with detectable EBV and CMV 
viral DNA showed rapid resolution (see below). The resolution of EBV and CMV activation and 
the absence of an increased rate of infectious adverse events suggest that the duration of functional 
effects of teplizumab on T-cells may be affected by their avidity for autoantigens, viral or other 
antigens.  Subsequent mechanisms involved in the therapeutic effects are incompletely understood. 
2.3. 
Safety Experience with Teplizumab 
Much of the safety experience with teplizumab are in Stage 3 T1D individuals. In the Protégé and 
other clinical studies, teplizumab is generally very well tolerated. In general, there are no major 
differences in overall adverse events (AEs) of clinical concern and serious adverse events (SAEs) 
between teplizumab and placebo groups. The most common AEs associated with teplizumab are 
a decrease in white blood cell counts, nausea and/or vomiting, upper respiratory infections or 
nasopharyngitis and elevations in AST or ALT and anemia, all usually mild or moderate. The most 
frequent observation is a decrease in white blood cell count (WBC), including, in order, transient 
lymphopenia, leukopenia, and neutropenia. Transient lymphopenia has occurred in ~2/3 of 
teplizumab recipients and is usually mild or moderate, which is consistent with 
teplizumab’s mechanism of action (Sherry 2011, Hagopian 2013). These events are usually 
self-limited and occur with teplizumab dosing and spontaneously reconstitute. For example, 
lymphocytes return to 80% of baseline levels within approximately 14 days of dosing. 
Approximately half of those who receive teplizumab develop a mild rash, sometimes 
pruritic, during dosing cycles, which spontaneously resolves within 7-14 days. Due to its 
mechanism of action, cytokine release syndrome is a potential concern with teplizumab dosing 
but occurs in <10% of teplizumab-treated individuals (for example ~6% in the Protégé study) 
and is usually mild-to-moderate and well 
The mean±95% CI are shown. The 
estimates and percent increase between 
the teplizumab vs. placebo groups are 
(3 months 46.5% (95%CI: 8.23, 
98.4%), 6 months 49% (4.13, 113%), 
18 months 15.9% (-14.2%, 56.4%). The 
analysis was performed with log-
transformed values by ANCOVA and 
corrected for the baseline values. The 
numbers along the X axis indicate the 
number of samples analyzed. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 15 
tolerated. Prophylactic administration of non-steroidal anti-inflammatory drugs (NSAIDs; eg, 
ibuprofen) and antihistamines (eg, diphenhydramine) appear to reduce the occurrence and the 
severity of its signs and symptoms significantly.  
In the Protégé study, severe AEs were noted in approximately 63% and 30% of teplizumab and 
placebo participants, respectively (Sherry 2011, Hagopian 2013). The most common (though 
occurring in less than 10% of teplizumab treated participants) was decreased white blood cell 
counts. Three deaths occurred and were evaluated by the principal investigator in accordance with 
International Conference on Harmonization (ICH)/Good Clinical Practice (GCP) guidelines. The 
specific causes of deaths and relationship with teplizumab are listed as: (1) “unknown” for which 
the relationship was listed as “none”; (2) “anterior myocardial infarction with ventricular 
tachycardia and cardio-respiratory arrest” for which the relationship was listed as “not related”; 
and (3) “diabetic ketoacidosis” for which the relationship was listed as “unlikely”.  
Despite the decrease in WBC, overall infections were not increased following teplizumab 
treatment. However, in the Protégé study there were 10 cases of herpes zoster (the result of 
reactivation of varicella zoster virus [VZV], the causative agent of chicken pox and shingles) in 
teplizumab-treated patients; all cases resolved without consequence. In the study, other herpes 
virus infections (eg, cytomegalovirus and Epstein-Barr virus) were not increased with teplizumab 
treatment (Sherry 2011, Hagopian 2013). 
More information is available in the Investigator’s Brochure (IB). 
In the recently completed TN-10 study, the adverse events in those with Stage 2 disease are shown 
below.  
Grade of adverse events in the TN-10 trial designated as possibly, probably, or definitely related 
to study drug are shown in Table 1 and adverse events by category related to study drug are shown 
in Table 2. 
Table 1: Grade of adverse events related to study drug 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 16 
Table 2: Adverse events by category and designated and possibly, probably, or definitely 
related to study drug. 
 Adverse Effect Category 
Teplizumab 
Placebo 
No. of 
Events# 
No. of 
Participants (%) 
No. of 
Events 
No. of 
Participants (%) 
Blood/Bone Marrow*** 
45 
33 (75) 
2 
2 (6.2) 
Dermatology/Skin*** 
17 
16 (36.4) 
1 
1 (3.1) 
Pain 
11 
5 (11.4) 
5 
3 (9.4) 
Infection 
8 
5 (11.4) 
5 
3 (9.4) 
Gastrointestinal 
5 
4 (9.1) 
3 
3 (9.4) 
Metabolic/Laboratory 
7 
4 (9.1) 
2 
2 (6.2) 
Pulmonary/Upper Respiratory 
6 
4 (9.1) 
0 
0 (0) 
Constitutional Symptoms 
3 
2 (4.5) 
0 
0 (0) 
Allergy/Immunology 
2 
2 (4.5) 
0 
0 (0) 
Cardiac General 
1 
1 (2.3) 
1 
1 (3.1) 
Endocrine 
0 
0 (0) 
2 
2 (6.2) 
Vascular 
1 
1 (2.3) 
1 
1 (3.1) 
Neurology 
1 
1 (2.3) 
0 
0 (0) 
Ocular/Visual 
1 
1 (2.3) 
0 
0 (0) 
Musculoskeletal/Soft Tissue 
2 
1 (2.3) 
0 
0 (0) 
Hepatobiliary/Pancreas 
0 
0 (0) 
1 
1 (3.1) 
Syndromes 
1 
1 (2.3) 
0 
0 (0) 
Hemorrhage/Bleeding 
1 
1 (2.3) 
0 
0 (0) 
Total Events and Individuals 
112 
44 (100) 
23 
32 (100) 
One individual who was treated with teplizumab, was diagnosed with serum sickness and received 
an abbreviated course of prednisone. This adverse event is captured under “pain” (of joints) above. 
Similar to previous studies with teplizumab in new onset type 1 diabetes patients, the lymphocyte 
count declined to a nadir on day 5 by 72.3% (interquartile range: 82.1, 68.4%) (p<0.0001) (Figure 
3). Fifteen (34.1%) of the grade 3 events in the teplizumab group involved lymphopenia during 
the first 30 days after study drug administration. The lymphocyte counts recovered quickly: 
Lymphopenia resolved in all participants by day 45 except in 1, whose counts returned on day 105. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 17 
Figure 3: Absolute lymphocyte counts in the study groups are shown over the first 7 weeks 
after enrollment 
A spontaneously resolving rash, as previously noted, occurred in 36% of teplizumab-treated 
participants. The rates of infection were similar in the two treatment arms. 
Anti-CD3 mAb treatment has been associated with Epstein-Barr virus (EBV) reactivation (Herold 
2003, Mach 1992). At entry, 30 participants (39%) (16 teplizumab and 14 placebo) had antibodies 
against EBV. At weeks 3-6 after study drug treatment, there was quantifiable EBV DNA in whole 
blood in 8 of the seropositive participants – all in the teplizumab group, one of whom had 
symptoms of pharyngitis, rhinorrhea, and cough on day 38. In these participants, the EBV DNA 
levels were below the level of quantification between day 43 and 134 (average 77 days). At entry, 
17 participants (10 teplizumab and 7 placebo) had antibodies against cytomegalovirus (CMV). 
One teplizumab participant, who was CMV seropositive, had detectable levels of CMV DNA at 
day 20 that was undetectable by day 42. 
2.4. 
Use of Teplizumab in Children 
The majority of new cases of T1D occur in children under the age of 18.  Moreover, given that the 
duration of diabetes is a significant risk factor for the development of diabetic complications and 
the clearly recognized difficulty in attaining excellent metabolic control of diabetes during 
adolescence. Diagnosis of T1D before the age of 20 incurs greater morbidity and loss of life years 
than when the diagnosis is made in adulthood. In the TN-10 trial, 72% of the participants were 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 18 
children. The adverse event experience was not significantly different in adults and children. 
Altogether, more than 470 children have received teplizumab in clinical trials.  
The study procedures, while greater than minimal risk, offers the possibility of benefit due to the 
close monitoring for all participants and the delay in diagnosis of T1D.  Assent of children along 
with consent of their guardians will be obtained, as appropriate, prior to any study procedures.    
Please refer to the Teplizumab IB for further non-clinical and clinical information on the antibody. 
2.5. 
Benefit/Risk Assessment 
Type 1 diabetes (T1D) is an autoimmune disease that results in a severe metabolic disease of 
glucose dysregulation. T1D is associated with significant short- and long-term complications and 
early death. Even with the best metabolic control using the most current insulins and glycemic 
monitoring devices, these risks are not eliminated. There is an urgent need to develop a disease 
modifying therapy for T1D. 
Clinical studies with teplizumab in T1D have shown that it is effective in preserving beta 
cell function (as measured by C-peptide) and hence endogenous insulin production (Herold 
2019). In the previous Protégé Study, teplizumab resulted in a statistically significant 
preservation of C-peptide, compared to placebo, at 2 years. As described in natural history 
studies, preservation of residual beta cell function (as measured by C-peptide levels) is 
protective 
against 
short-(hypoglycemic episodes) and long-term complications of T1D, 
including retinopathy, nephropathy and other cardiovascular events (Steffes 2003, Sorensen 
2013, Lachin 2014, Kuhtreuber 2015). 
The main risks of teplizumab consist of transient lymphopenia and transient self-limited (mild to 
moderate) rash. Cytokine release syndrome is infrequent (~6%) and there is no overall increased 
risk of clinical infection or cancers. 
Given the potential for important benefit in short- and long-term T1D outcomes compared to the 
transient, mild to moderate risks of teplizumab, the prospect of benefit outweighs the risk 
of participating in this study. 
More detailed information about the known and expected benefits and risks and 
reasonably expected adverse events of teplizumab may be found in the IB. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 19 
3.
Objectives and Endpoints
Objectives 
Endpoints 
Primary 
•
To evaluate the safety and tolerability
of teplizumab treatment, administered
intravenously (IV) to participants in
the TN-10 trial who have developed
T1D.
•
Incidence of treatment-emergent
adverse events (TEAEs), adverse
events of special interest (AESIs), and
serious adverse events (SAEs)
Secondary 
•
To evaluate the pharmacokinetics
(PK) and immunogenicity of
teplizumab
•
To evaluate whether teplizumab
treatment reduces the loss of β cells,
over 78 weeks (18 months), in
individuals with recent diagnosis of
T1D.
•
To evaluate key clinical parameters of
diabetes management, including
insulin use, hemoglobin A1c (HbA1c),
and clinically important hypoglycemic
episodes over 78 weeks
•
To evaluate whether treatment with
teplizumab increases the frequency of
exhausted T cells
•
Levels of teplizumab in the serum and
anti-drug antibodies
•
The area under the time-versus-
concentration curve (AUC) of
C-peptide after a 4-hour (4h) mixed
meal tolerance test (MMTT), a
measure of endogenous insulin
production and β cell function, over
78 weeks
•
HbA1c levels; insulin use, defined as
a daily average in units per kilogram
per day (U/kg/day); and frequency of
clinically important hypoglycemic
episodes over 78 weeks
•
Frequency of CD8+ TIGIT+ KLRG1+
T cells
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 20 
4.
Study Design
4.1. 
Overall Design 
The is a single-arm, multicenter, open-label clinical trial. 
Teplizumab-treated and placebo participants in the TN-10 trial who develop clinical type 1 
diabetes after the conclusion of that trial, are eligible to enroll and receive teplizumab treatment in 
this open-label study within one year of clinical T1D diagnosis.  
Number of Participants: 
Up to 30 participants may be enrolled in this study. 
Treatment and Study Duration: 
All participants will receive a 12-day course of teplizumab given through daily IV infusion. 
Participants will have a screening period of up to 4 weeks, a treatment period of 12 days, and a 
follow-up period of up to 78 weeks (18 months) from the first dose of treatment.  
4.2. 
Scientific Rationale for Study Design 
It is recognized that participants eligible for this study have undergone further decline in beta cell 
mass and function since their participation in the TN-10 trial, leading to the need for exogenous 
insulin replacement in order to maintain glycemic control. At this juncture, it is critical to preserve 
the remaining beta cell function as this leads to better short-term (ie, hypoglycemic episodes) and 
long-term outcomes including retinopathy, nephropathy and other cardiovascular events (Steffes 
2003, Sorensen 2013, Lachin 2014, Kuhtreuber 2015). Phase 2 and Phase 3 clinical trials with 
teplizumab have consistently shown significant preservation of beta cell function as measured by 
C-peptide in patients with newly diagnosed T1D (Hagopian 2013; Herold 2013a; Herold 2013b; 
Herold 2019). Therefore, it is anticipated that the benefit of teplizumab treatment on preservation 
of beta cell function may be realized in previous participants of the TN-10 study who now have 
developed clinical type 1 diabetes.
Between 20% and 56% of teplizumab treated patients develop anti-drug antibodies that may be 
neutralizing antibodies (NAb). These antibodies can be detected within 2 weeks after the drug has 
been given. They may affect the immunologic effects of additional courses of teplizumab 
treatment, but a safety concern has not been identified – second courses of teplizumab did not have 
an increased frequency of adverse events compared to the first course. In this study, the responses 
to teplizumab treatment in participants with and without anti-drug antibodies will be analyzed. The 
time interval between the first (under the TN-10 protocol) and second course of teplizumab 
treatment in this study (PRV-031-002) is longer than has previously been tested and therefore, the 
effect of anti-drug antibodies is not known. Thus, these study participants are different from those 
who previously have received two courses of teplizumab. As eligible and consenting placebo 
participants in the TN-10 trial will also be treated with teplizumab upon the diagnosis of clinical 
T1D, the immunologic effects of teplizumab in the placebo group, who will receive teplizumab 
for the first time, will serve as a comparator to individuals previously treated with teplizumab. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 21 
4.3. 
Justification for Dose 
In previous clinical studies of teplizumab in T1D, a number of dosing regimens have been 
evaluated that have included children and/or adults. These studies have evaluated single multi-day 
courses of teplizumab and 2 multi-day courses either 6 or 12 months apart. Although the goals, 
stage of T1D, and entry criteria differed between these studies, all have shown that teplizumab was 
well tolerated with an acceptable safety profile, and an ability to preserve β cell function and 
improve clinical outcomes in study populations or specific sub-populations. It is these effects that 
support further evaluation and clinical development of teplizumab as a first-in-class therapy for 
children and adolescents newly diagnosed with T1D (Herold 2002, Sherry 2011, Hagopian 2013, 
Herold 2005, Herold 2013a, Herold 2013b).  
Of note, the 14-day regimen evaluated in Protégé (and other previous studies including the TN-10 
The most extensive and detailed evaluation of teplizumab in T1D is from the Phase 2/3 “Protégé” 
study in which 2 multi-day courses of teplizumab were given 6 months apart in children and adults 
8 to 35 years old who were diagnosed with T1D within 12 weeks of T1D diagnosis. In that study, 
three dosing regimens of teplizumab were evaluated and included: (1) a 14-day course with a 
cumulative dose of 9.0 mg/ m2; (2) a 14-day course with a cumulative dose of 3.0 mg/ m2; and (3) 
a 6-day course with a cumulative dose of 2.4 mg/ m2. In the open-label Phase 2 segment of Protégé, 
participants received the 14-day regimen of 9.0 mg/m2/course at enrollment and 26 weeks later to 
assess safety and tolerability before the double-blind study was started. The Phase 3 segment 
studied the three teplizumab dosing regimens in comparison to placebo. The open label Phase 2 
segment of Protégé enrolled 38 participants, and the randomized, double-blind Phase 3 segment 
enrolled 207, 102, and 106 teplizumab-treated participants, respectively, and the placebo arm 
98 participants (Sherry 2011, Hagopian 2013).  
In addition to assessments of safety and efficacy, the Protégé study conducted extensive PK and 
immunogenicity evaluations. From this data, a detailed population PK model has been developed 
using a two-compartment (peripheral and central) model with saturable binding kinetics 
incorporating body surface area (BSA), proportional dosing, and teplizumab AUC, trough 
concentration, and peak concentration. These findings showed that PK was independent of age, 
gender, race, region, disease state or onset, although it was influenced by antidrug-antibody 
response. 
As described earlier, although the previously untested and unevaluated composite primary 
endpoint was not met in the entire study population of Protégé, a positive effect of teplizumab in 
T1D was confirmed in Protégé subpopulations, supporting findings from a number of previous 
clinical studies. Specifically, participants from certain regions (eg, the United States) who were 8-
17 years old, who had teplizumab initiated within 6 weeks of T1D diagnosis and with higher C-
peptide levels at study entry showed significant retention of endogenous insulin production 
through 2 years compared to placebo treated participants. 
A 14-day course necessitates participants and their parents or guardians (required by pediatric 
participants) to be available every day for 2 entire consecutive weeks and associated weekends. 
This requirement is seen to be particularly challenging to children and adolescents and their 
families due to work and school obligations and therefore may have a negative influence on 
recruitment and retention as well as a significant bias in a pivotal study.  
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 22 
With the realization of the potential negative impact on many aspects of the clinical trial of a 14-
day treatment course combined with the significant experience with teplizumab, in this study we 
propose to use a regimen that is more acceptable to participants and their families that delivers 
clinically overlapping exposures that could support approval for teplizumab. 
We propose to modify the dosing regimen to 12 days: Day 1: 106 µg/m2, Day 2: 425 µg/ m2, and 
Days 3-12: 850 µg/ m2/day. During the first 2 days of ramp-up, approximately 5.9% of the total 
dose is given. In the last 10 days, ~94% of the total dose is delivered in equally divided doses.  
Compared to a 14-day dosing regimen, this study’s 12-day teplizumab course has a modified 2-
day ramp-up phase but also has a 10-day fixed-, maximal dosing period like the 14-day course. 
Based on calculations, the amount of teplizumab given in the 12- and 14-day approach only differs 
by 0.005 mg/m2. But due to practical aspects of rounding and calculating the BSA and a given 
dose, these courses are considered clinically equivalent.  
As shown in the PK simulations in Figure 4, the first 2 doses in the 14-day regimen are calculated 
to have very low, almost negligible, serum concentrations with serum concentrations of the last 11 
doses of both regimens that are superimposable. In both instances, >90% of the total dose per 
course is given in the final 10 days in similar equally divided doses (0.850 mg/m2 in the 12-day 
course versus 0.826 mg/m2 in the 14-day course). The first 2 days of the 14-day course delivers a 
nominal amount (ie <2.0%) of the course’s total dose. The final trough concentrations (426±220 
ng/mL [14-day regimen] and 435±225 ng/mL [12-day regimen]), as well as the elimination times 
are overlapping in both regimens.  
Figure 4: PK Simulation of 12-Day and 14-Day Dosing Regimens 
Taken together, this study will evaluate a more participant and family-friendly approach to deliver 
the same dose of 9.0 mg/m2 of teplizumab over a course of 12 days, which has been shown to be 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 23 
well tolerated, safe and effective in preserving β cell function. Because of the similarities and 
overlap of the regimens and exposures, data from this study can be combined with data from other 
studies to support the application and approval for teplizumab as a disease modifying therapy for 
the study population in those recently diagnosed with T1D. 
4.4. 
End of Study Definition 
A participant is considered to have completed the study if he/she has completed all phases of the 
study including the last visit shown in the Schedule of Events (Section 1.3). 
The end of the study is defined as the date of the last visit of the last participant in the study. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 24 
5.
Study Population
5.1. 
Inclusion Criteria 
Participants are eligible to be included in the study only if all of the following criteria are met: 
1. Previous participant in the TN-10 study.
2. Participant has received a diagnosis of T1D after the conclusion of the TN-10 study,
according to the criteria from the American Diabetes Association (ADA).
3. Participant is able to initiate teplizumab treatment required in this study within 1 year of
T1D diagnosis.
4. If participant is female with reproductive potential, she must have a negative pregnancy
test prior to enrollment and be willing to avoid pregnancy for at least 18 months from the
first dose of study drug.
5. Participant is willing and medically able to postpone live vaccine immunizations for 1 year
after receiving the last dose of study drug in this study.
6. Participant is willing to forego other forms of experimental treatment during the entire
study.
7. Participant and/or guardian has given informed consent and assent as applicable.
5.2. 
Exclusion Criteria 
Participants will be excluded from the study if any of the following criteria is met at screening or 
before the first dose is given:  
1. Lymphopenia (< 1000 lymphocytes/µL)
2. Neutropenia (< 1500 polymorphonuclear cells [PMNs]/µL)
3. Thrombocytopenia (< 150,000 platelets/µL)
4. Anemia (hemoglobin < 10 g/dL)
5. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 x upper limit
of normal (ULN)
6. Total bilirubin >1.5 x ULN. Exception: participants with the diagnosis of Gilbert’s
syndrome may be eligible if they have no other causes leading to hyperbilirubinemia.
7. Chronic active infection except localized skin infections. This may be discussed with
the Medical Monitor on a case by case basis.
8. Participant has any of the following regarding tuberculosis (TB):
•
A history of latent or active TB
•
Signs and/or symptoms of TB
•
Recent close contact with a person with known or suspected active TB, unless
appropriate isoniazid prophylaxis for tuberculosis was given
•
A history of a chest X-ray consistent with active TB or old, inactive TB,
•
A history of a positive purified protein derivative (PPD) skin test result (>10 mm
induration)
•
At screening is positive or repeatedly indeterminate with an approved interferon-
gamma release assay (IGRA; eg, QuantiFERON-TB test) or PPD.
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 25 
•
If required by local, regional or national regulations, a recent (within 3 months)
chest X-ray or one conducted at screening read by a qualified radiologist consistent
with current, active TB or old, inactive TB
9. Vaccination with a live virus within 8 weeks before first dose of the study drug
10. Vaccination with a killed virus within 4 weeks before first dose of the study drug
11. A history of infectious mononucleosis within the 3 months before screening.
12. Laboratory or clinical evidence of acute infection with EBV or CMV.
13. Serological evidence of current or past human immunodeficiency virus (HIV), hepatitis
B virus (HBV) or hepatitis C virus (HCV) infection.
14. Currently pregnant or lactating or planned pregnancy within 18 months 2 years after
receiving the last dose of the study drug
15. Chronic use of steroids or other immunosuppressive agents.
16. A history of asthma or atopic disease requiring chronic corticosteroid treatment.
17. Untreated hypothyroidism or active Graves’ disease.
18. Current use of non-insulin pharmaceuticals or dietary supplements that may affect
glycemic control.
19. Participation in any therapeutic drug or vaccine clinical trial within 12 weeks before the
first dose of study drug.
20. Any condition that, in the opinion of the investigator, would interfere with the study
conduct or the safety of the participant.
5.3. 
Enrollment
Potential study participants will be identified through previous participation in the TN-10 trial. 
TN-10 participants, regardless of whether they received teplizumab or placebo in that study, are 
invited and screened for this study if they have been diagnosed with T1D and can receive 
teplizumab within 12 months of the diagnosis. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 26 
6.
Study Drug Dosing
6.1. 
Study Drug Administered 
All participants will receive an IV infusion of teplizumab once daily for 12 consecutive days. 
The participant’s body surface area (BSA) will be calculated by the study pharmacist using the 
Mosteller formula. The BSA will be calculated on Study Day 1 and will be based on the 
participant’s height and weight on that day. This calculation will be used for the doses given over 
the entire 12-day treatment course. For dosing purposes, the participant’s BSA should be rounded 
up to the nearest tenth place regardless of the number in the hundredth position. For example, if 
the BSA is 1.61 m2, it will be rounded up to 1.7 m2; if the BSA is 1.67 m2, it will also be rounded 
up to 1.7 m2. The dose should be rounded to the nearest whole number.   
The drug dosing is: 
Day 1: 106 µg/m2 
Day 2: 425 µg/m2 
Days 3-12: 850 µg/m2 daily 
Total per course: 9.0 mg/m2 
The Mosteller formula is as follows: 
BSA (m²) = ([Height(cm) x Weight(kg)]/ 3600)½ 
Teplizumab is administered via an IV infusion over a minimum of 30 minutes in the research or 
hospital setting. The daily time of the infusion should be consistent but may be adjusted by a time 
window of ±4 hours on each day. If there are signs or symptoms of infusion reaction during the 
60-minute observation period, the participant should be observed for an addition al 60 minutes or
until the reaction resolves, whichever is longer.
6.2. 
Preparation/Handling/Storage/Accountability 
The formulation of teplizumab consists of 10 mM sodium phosphate, 150 mM sodium chloride, 
and 0.05 mg/mL Tween 80, with pH 6.1.  
Final drug product will be provided at a concentration of 1 mg/mL for a total of 2 mg of recoverable 
drug product per vial. 
The vials should be stored upright at 2°–8°C and must not be frozen or shaken. Because there is 
no preservative and drug loss occur over time, administration of the study drug should begin as 
soon as possible and no later than 2 hours after preparation. The drug may be prepared into a bag 
for infusion and delivered by gravity or by infusion pump. Intravenous drug delivery devices, 
including IV bags and tubing, must be composed of polyvinyl chloride (PVC). Refer to Pharmacy 
manual for details. 
Laboratory studies that will be obtained prior to each dose are described in the Schedule of Events 
(Section 1.3) and Appendix 2 (Section 10.2). The same-day results of chemistries (including liver 
function tests [LFTs]), WBC counts, hemoglobin, hematocrits and platelets must be reviewed prior 
to commencement of the drug infusion on each dosing day. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 27 
6.3. 
Concomitant Therapy 
6.3.1. 
Diabetes Management and Insulin Use 
All participants should receive intensive diabetes management of their T1D using approved 
therapies according to the recommendations of ADA to achieve glucose levels that appear to 
decrease some of the short-term and long-term sequelae of T1D. Currently the glycemic targets by 
the ADA are focused at management strategies to achieve an HbA1c level of <7.5% (58 
mmol/mol) for individuals 17 years old and younger and <7.0% (53 mmol/mol) for those 18 years 
and older, while minimizing severe or frequent hypoglycemic events. If there are local, regional, 
or national recommendations to be followed that supersede ADA recommendations, these 
glycemic control targets (ie, HbA1c or glucose levels) should not be more liberal (ie, higher) than 
the ADA recommendations. The Investigator will document, in the case report form (CRF) and/or 
the source documents, the glycemic goals and the guidelines being followed.  
The glycemic goal should be attempted through proper glycemic monitoring, administration of 
exogenous insulin, and monitoring of activity level and diet. Exogenous insulin may include rapid, 
intermediate, and/or long-acting insulins, administered intermittently or via the use of a personal 
insulin pump. Blood glucose levels should be measured at least 4 times a day, including before 
meals and before bedtime. Approaches to achieve these HbA1c goals will be the responsibility of 
the participant, their caregivers, and their healthcare providers.  
Insulin use, including the type of products, dosages, and dosing schedules, is expected to change 
during the course of the study. As part of routine T1D clinical care, if the caring physician judges 
it to be clinically appropriate, a participant’s insulin dose may be increased, reduced, or even 
discontinued.  
Insulin Discontinuation 
If a participant has achieved a HbA1c level of ≤6.5% with insulin use of ≤0.25 U/kg/day, insulin 
therapy can be discontinued. The participant’s blood glucose and HbA1c levels should continue 
to be monitored per protocol, and urine ketones should be tested at home once a day. During 
routine blood glucose monitoring, if the participant’s blood glucose level exceeds 200 mg/dL 
and/or urine ketone level is moderate or greater, the participant should consult with their primary 
physician and/or the clinical site staff for further evaluation. If the fasting blood glucose exceeds 
126 mg/dL or HbA1c exceeds 6.5%, as documented by repeat testing, the resumption of insulin 
therapy should be considered. 
6.3.2. 
Prophylactic Medications 
Ibuprofen and antihistamine will be administered prophylactically prior to teplizumab infusion on 
the first 5 days of treatment. After Day 5, the use of pre-medication is optional.  If ibuprofen is 
contraindicated, acetaminophen should be given instead. Further dosing of ibuprofen, 
antihistamines, and/or acetaminophen can be used as needed for fever, malaise, headache, 
arthralgia, or rash. All prophylactic medications administered should be recorded on the 
concomitant medication CRF.  
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 28 
6.3.3. 
Prohibited Medications 
Participants will be instructed not to use steroids, (eg, prednisone [topical or systemic]), other 
immunosuppressive agents, or chronic inhaled or nasal corticosteroids during this trial in order to 
reduce infectious risks and to prevent possible impact on diabetes outcome. A short course (ie, 
approximately 2 weeks or less) of systemic (including oral, inhaled or parenteral) corticosteroids 
may be used for treatment of a transient condition. In the event of a medical condition requiring 
glucocorticoid treatment, they may be used after discussion with the Medical Monitor. However, 
no individual will be withdrawn from analysis if this occurs. 
Participants will be instructed not to receive live vaccinations for 1 year after dosing.  In addition, 
participants should not receive vaccination with a killed virus vaccine within 8 weeks after the last 
dose of the study drug, unless this is approved by the Medical Monitor.  
6.3.4. 
Emergency Precautions 
Before every infusion of study drug, appropriate emergency equipment and trained personnel 
should be present. At a minimum, the following will be available: 
•
Epinephrine 1 mg doses (or resuscitation dose recommended by local, regional or national
authorities) for IV injection
•
Dexamethasone 10 mg (or equivalent glucocorticoid) for IV injection
•
Diphenhydramine: 50 mg (or equivalent antihistamine) for IV injection
•
Resuscitation equipment and other supplies for the emergency management of an
allergic/toxic reaction.
If AEs develop during infusion, the infusion may be slowed or interrupted, as determined by the 
Investigator. If interrupted, the infusion may be restarted, preferably at a slower rate, if deemed 
reasonable by the Investigator. Any changes in the infusion rate must be recorded with the reason 
for the change. In any cases of AEs determined or suspected to be related to the infusion of the 
study drug, the participant should be treated using appropriate medical practices and procedures.  
During or after the infusion of study drug, if a participant experiences any of the following signs, 
the participant will be observed, and the severity of the reaction will be evaluated:  
•
Fever of >38.5°C (101.3°F)
•
Rigors or myalgias
•
Pain, swelling, or edema near the infusion site
•
Local or systemic rash
•
Mucosal congestion or edema
•
Significant (eg, 30%) drop in systolic or diastolic blood pressure or increase in resting heart
rate
•
Hyperventilation, wheezing or difficulty breathing
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 29 
•
Change in mental status
Acetaminophen (or similar drug) and/or additional NSAID may be given if needed, glucocorticoid 
treatment may be considered. The participant should be treated using appropriate medical practices 
and procedures. The participant will be continuously monitored until their clinical status returns 
to baseline or is significantly improved. 
If an infusion is discontinued, an estimate on the volume of the infusion given and a quantitative 
assessment of the remaining volume should be documented. 
The Medical Monitor should be notified of all cases of actual or suspected infusion reactions and 
AEs thought to be related to the study drug infusion. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 30 
7.
Interruption or Discontinuation of Study Drug Treatment and
Participant Discontinuation/Withdrawal
A participant will not be automatically withdrawn from the study if they temporarily or 
permanently discontinue study drug before the end of the treatment course. If a participant 
permanently discontinues study drug for any reason, they should be encouraged to return for the 
Early Termination visit.  
Unless lost to follow-up, SAEs must be reported for participants who withdraw early from the 
study for one year after their last study drug dose (Section 8.4.1).  
7.1. 
Interruption of Study Drug Treatment 
Blood samples will be drawn for clinical laboratory tests, as listed in Section 1.3, and the results 
will be reviewed by the Investigator before the study drug can be administered on each day of the 
treatment. 
Study drug dosing may be interrupted temporarily, for an individual participant, if any of the 
following medically important events occur:   
•
A significant infection, defined as:
-
Any severe infection meeting SAE criteria (Section 10.3.2), or
-
Any clinically significant infection not meeting SAE criteria but per Investigator’s
judgment might put the participant at risk, or
•
An SAE, a study drug-related severe AE, or an AE that puts a participant at risk, defined
as:
-
Any SAE or
-
Any severe AE that is considered related (possibly, probably, or very likely related) to
study drug (as defined in Section 10.3.1), including but not limited to an infusion
reaction categorized as a severe or SAE by the Investigator.
-
Any AE (including mild or moderate) of any relatedness to study drug that leads to the
Investigator to believe that further dosing of study drug during that course puts the
participant at undue risk.
•
If any of the following out-of-range lab results is observed (normal range per local lab
reference ranges), the test may be repeated on the same day. If the repeated test result
normalizes, that day's dose may be given. If the value is still in the indicated range or
worsens, or if the test cannot be repeated on the same day, that day's dose should be
withheld.
-
ALT and/or AST >3 x ULN but ≤5 x ULN
-
Total bilirubin >2 x ULN but ≤3 x ULN
-
Platelet count >50,000 but ≤100,000
-
Hemoglobin >8.5 g/dL but ≤10 g/dL
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 31 
Note: When clinical and laboratory abnormalities are considered related to T1D disease activity 
(ie, hypoglycemia and hyperglycemia) and study drug is not considered a contributing factor, 
administration may not need to be modified. The site Investigator should consult with the Sponsor 
if this is encountered.  
If the above events resolve within 2 days, study drug dosing may be resumed according to the 
original schedule. The treatment course will not be extended beyond 12 days. 
If the above events do not resolve after 2 consecutive days of interruption, the Medical Monitor 
must be consulted regarding continuation of study drug dosing. 
7.2. 
Discontinuation of Study Drug Treatment 
The study drug should be discontinued permanently if any of the following events occur: 
•
The Investigator believes that for safety or tolerability reasons it is in the best interest of
the participant to discontinue study drug.
•
A female participant becomes pregnant. Note: The “Pregnancy Report Form” should be
submitted for all pregnancies that occur in a study participant. Pregnancy should be
followed for outcome and any premature terminations reported. The health status of the
mother and child including date of delivery and the child’s sex and weight should be
reported after delivery.
•
A severe infection requiring inpatient hospitalization or repeated doses of parenteral
antibiotics
•
A severe hypersensitivity reaction, such as anaphylaxis or angioedema with or without
requiring hemodynamic support (ie, epinephrine and/or blood pressure medications) or
mechanical ventilation, to the study drug or an infusion reaction (including cytokine release
syndrome) with signs or symptoms categorized as an SAE.
•
The participant has a clinically significant cardiovascular event.
•
The participant is diagnosed with a malignancy, lymphoma or a lymphoproliferative
disorder.
•
If any of the following lab values is observed (normal range per local lab standard), the
next study drug dose should be held until a repeat test is obtained and evaluated. If the out-
of-range result is confirmed on two consecutive dosing days, the participant should be
discontinued from any further study drug treatment.
-
ALT and/or AST >5X ULN
-
Total Bilirubin >3X ULN
-
ALT and/or AST >3X ULN AND Total Bilirubin >2X ULN (Hy’s Law criteria)
-
Platelet count <50,000/µL
-
Neutrophil count <500 cells/µL
-
Hemoglobin of <8.5 g/dL
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 32 
•
Any ≥Grade 3 AE during dosing other than:
-
Lymphopenia
-
Neutropenia
-
Low total WBC
-
Hypoglycemia or symptoms and signs of a hypoglycemic episode
-
Hyperglycemia or symptoms and signs related to hyperglycemia
-
Fatigue or malaise
-
Insomnia
-
Cheilitis
-
Dry skin
-
Nail changes
-
Hot flushes or flashes
-
Headache
-
Myalgia
-
Flu-like syndrome
•
Any medically important event such as a concurrent illness, complications, or abnormal
laboratory result that, in the opinion of the Investigator, contraindicates continued dosing
of the participant
•
Administration of prohibited medication or dose modification of concomitant medications
that necessitate discontinuation of study drug administration
•
A general lack of compliance with study visits and procedures per study team or a missing
3 consecutive study drug administrations
The Study Medical Monitor must be notified within 24 hours of any participant who is permanently 
discontinued from study drug dosing. Participants who have study drug dosing permanently 
discontinued will be encouraged to receive follow-up care and evaluation as scheduled, unless 
consent for follow-up is withdrawn. 
7.3. 
Participant Discontinuation/Withdrawal from the Study 
A participant will be withdrawn from the study for any of the following reasons: 
•
Lost to follow-up
•
Withdrawal of consent/assent
•
Death
•
Study Investigator or Sponsor, for any reason, decides the participant should be withdrawn
from the study.
•
Pregnancy (see Section 8.4.5)
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 33 
When a participant withdraws before completing the study, the Sponsor is to be notified and the 
reason for withdrawal is to be documented.  
If a participant withdraws from the study before the end of study, all attempts should be made to 
obtain Early Termination assessments. 
7.4. 
Lost to Follow-up 
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site. 
If a participant is lost to follow-up, every reasonable effort must be made by the study-site 
personnel to contact the participant and determine the reason for discontinuation/withdrawal. The 
measures taken to follow-up must be documented. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 34 
8.
Study Assessments and Procedures
The assessments and procedures required in this study are listed in the Schedule of Events table in 
Section 1.3.  
It is recognized that the amount of blood that may be drawn for research purposes in children and 
adults may not exceed certain limits, both at a single visit and over a set time period. In any 
participant whose clinical condition might be adversely affected by removal of the blood volumes 
stated in this protocol, for example, a participant with significant anemia or compromised cardiac 
output, Investigators should consider further limiting the volume of blood withdrawn for research 
purposes. In instances of medical need, it is the responsibility of the Investigator and/or 
participant’s healthcare providers to determine if blood draws in excess of the protocol-stated 
volumes should occur. Because blood sampling in excess of those mandated by the protocol may 
be taken in the course of providing care during this study, sites must ensure that all instances of 
blood collection in excess of permitted volumes are recorded and justified in the participant’s 
record. 
Additional blood volumes may be collected by individual sites and will be included in the site-
specific informed consent form. 
8.1. 
Screening and Baseline Assessments 
8.1.1. 
Screening (Visit -1) 
This study will enroll former participants of the TN-10 protocol who have developed T1D within 
the past 12 months.  
The participant/parent/guardian will be asked to sign an informed consent and/or assent describing 
the purpose, risks, and benefits of screening for the trial. A participant/parent/guardian’s signature 
indicates that he/she understands the potential risks and benefits of study participation. During the 
screening visit, clinical tests will be performed to determine eligibility, as described in the 
Schedule of Events (Section 1.3).  
Any participant either not eligible or not willing to be enrolled into this study is eligible for 
continued follow-up as part of the Long-Term Investigative Follow-Up in TrialNet Study (LIFT, 
TN-16).  
8.1.2. 
Baseline Assessments and Initiation of Teplizumab Treatment (Visit 1) 
Participants will undergo a 4-hour mixed meal tolerance test (4h MMTT) and other baseline 
clinical tests at Visit 1, as indicated in the Schedule of Events (Section 1.3). All relevant laboratory 
and clinical data will be reviewed to confirm eligibility and document baseline values. 
Subsequently, eligible participants will receive the first dose of teplizumab IV infusion at the same 
visit. 
8.2. 
Post-Baseline Visits 
Participants will complete a 12-day course of teplizumab treatment and return to the study site for 
follow-up assessments through Week 78, as outlined in the Schedule of Events (Section 1.3). 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 35 
Participants who discontinue the study before the final visit at Week 78 should undergo the 
assessments listed for the Early Termination (ET) visit.  
8.3. 
Efficacy Assessments 
During the study period, all participants will be closely monitored for T1D control, insulin use, 
AEs and laboratory abnormalities, undergo 4-hour MMTT every 6 months, and provide blood 
samples for analyses.  
8.3.1. 
Metabolic Assessments 
A 4h-MMTT will be performed at study entry (Visit 1) and every 6 months. At each study visit, 
the amount of exogenous insulin that is being taken over the 3 days prior to the visit will be 
documented. HbA1c levels will be measured prior to study drug administration and at each of the 
designated study visits. 
8.3.1.1. 
Hypoglycemia 
Instances of significant impairment consistent with hypoglycemia and requiring assistance (ie, 
often referred to as “severe” hypoglycemia), even in the absence of a blood glucose reading, are 
classified as “Level 3 Hypoglycemia” (IHSG 2017). Level 3 hypoglycemia may include 
cognitive impartment, altered/loss of consciousness, confusion, seizure, syncope/fainting, or 
coma, and support may be general assistance, glucagon, or oral carbohydrate (ie, fruit juice or 
glucose tablets). Such episodes may or may not require medical attention or hospitalization. 
This study will consider clinically significant hypoglycemia to be Level 3 or greater 
hypoglycemia as defined below. 
For AE reporting purpose, the severity of a hypoglycemia event should be identified by the 
Investigator and classified according to CTCAE v5.0 as follows: 
•
Grade 3 hypoglycemia: 30-39 mg/dL (1.7–2.1 mmol/L). This is considered severe or
medically significant but not immediately life-threatening. Hospitalization or
prolongation of hospitalization is likely indicated. It is considered disabling and limits
self-care.
•
Grade 4 hypoglycemia: ≤29 mg/dL (1.6 mmol/L). This is considered life threatening (eg,
seizures) with urgent intervention indicated.
•
Grade 5 hypoglycemia: Hypoglycemia resulting in death.
8.3.2. 
Mechanistic Outcome Assessments 
Immune and gene-expression tests to further understand mechanisms that may be underlying the 
T1D disease process and response to therapy will be conducted. For this purpose, plasma and 
serum samples for the analyses of peripheral blood mononuclear cells (PBMCs), DNA, RNA, will 
be obtained at designated time points, and serum samples will be obtained during the MMTT. 
Planned mechanistic studies include but are not limited to the following: 
1. Immune cell phenotyping by flow cytometry: The markers that will be measured include
those analyzed in the original TN-10 study and other markers that are suggested by
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 36 
transcriptomic or other studies. Measurement of cell proliferation will be performed by 
staining with Ki67. The analysis will be done on PBMCs that will be frozen after collection 
and analyzed at a later time. Samples will be collected prior to the first dose of teplizumab 
and at the indicated intervals afterwards. In participants who received their first course of 
teplizumab during the TN-10 study, the results will be compared to the data from the first 
course of teplizumab administration.   
2. The transcriptional signature of changes in immune cells with teplizumab treatment by 
single cell RNAseq or similar technologies: These changes will be compared to the findings 
from the previous administration of teplizumab in those who are receiving the drug for a 
second time.  
3. The frequency and changes in phenotypes of diabetes antigen specific T cells: The 
frequency of these cells will be measured by Class I and/or Class II major 
histocompatibility complex (MHC) tetramer and T cell libraries. Frozen PBMCs will be 
used for this analysis.  
4. Metabolic function including glucose tolerance, patterns and magnitude of endogenous cell 
responses, and other markers of β cell stress and death.  
5. Analysis of changes in peripheral blood cells: The results of the CBC and differential tests 
will be used.  
6. Anti-drug antibodies and effects of these antibodies on responses to teplizumab: The titers 
of anti-drug antibodies and presence of neutralizing antibodies will be measured in samples 
collected before and after teplizumab administration. The presence or absence of these 
antibodies and the changes in immune cells will be analyzed.  
7. Epigenomic analysis of immune cell subsets: This analysis may involve techniques such 
as ATACseq will be performed on frozen cells and will be conducted after the initial 
transcriptomic studies. 
8.4. 
Safety Assessments 
Safety assessments include clinical safety laboratory tests, AE assessments, and pregnancy 
monitoring. Planned time points for all safety assessments are listed in Section 1.3. 
8.4.1. 
Adverse Events and Serious Adverse Events 
See Appendix 3 for the definitions of AEs, SAEs, and reporting instructions.  
AEs will be reported by the participant or, when appropriate, by a caregiver, surrogate, or the 
participant's guardian or legally authorized representative. 
Throughout the study, the investigator must record all AEs, including assessment of relatedness 
and severity (according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events [CTCAE]). The investigator should treat participants with AEs appropriately and 
observe them at suitable intervals until the events resolve or stabilize. 
8.4.1.1. 
Time Period and Frequency for Collecting AE and SAE Information 
All AEs will be collected from the signing of the informed consent form (ICF) until the follow-up 
visit at the time points specified in Section 1.3. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 37 
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in Appendix 3 in Section 10.3. The 
investigator will submit any updated SAE data to the sponsor within 24 hours of it being available. 
Investigators are not obligated to actively seek AE or SAE after conclusion of the study 
participation. However, if the investigator learns of any SAE, including a death, at any time after 
a participant has been discharged from the study, and he/she considers the event to be reasonably 
related to the study intervention or study participation, the investigator must promptly notify the 
sponsor. 
8.4.1.2. 
Method of Detecting AEs and SAEs 
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 in Section 10.3. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences. 
8.4.1.3. 
Follow-up of AEs and SAEs 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All AEs, SAEs, and AEs of special interest (AESI, as defined in 
Section 10.3.3), will be followed until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow-up (as defined in Section 7.4). Further information on follow-up 
procedures is provided in Appendix 3 in Section 10.3. 
8.4.1.4. 
Regulatory Reporting Requirements for SAEs 
Prompt notification by the investigator to the sponsor of an SAE is essential so that legal and 
regulatory obligations and ethical responsibilities towards the safety of participants and the safety 
of a study intervention under clinical investigation are met. 
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
sponsor will comply with country-specific regulatory requirements relating to safety reporting to 
the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), 
and investigators. 
For all studies, investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions (SUSAR) according to local regulatory requirements and sponsor policy and 
forwarded to investigators as necessary. 
8.4.2. 
Clinical Safety Laboratory Assessments 
See Appendix 2 (Section 10.2) for the list of clinical laboratory tests to be performed. 
The investigator should report any clinically relevant changes during the study as AEs. Clinically 
significant abnormal laboratory findings are those which are not associated with the underlying 
disease, unless judged by the investigator to be more severe than expected for the participant's 
condition. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 38 
8.4.3. 
Physical Examinations 
A complete physical exam includes evaluation of general appearance, head, eyes, ears, nose, and 
throat evaluation, neck palpation for thyroid, lymphadenopathy and tenderness, auscultation of the 
heart, lungs and abdomen, palpation of abdomen, evaluation of extremities and skin, and gross 
neurologic evaluation of strength, sensation and balance. 
A partial physical examination includes general appearance, head, eyes, and throat evaluation, 
neck palpation for thyroid, lymphadenopathy and tenderness, auscultation of the heart, lungs and 
abdomen, palpation of abdomen, evaluation of extremities and skin. 
Weight and height will be measured using calibrated scales. At each measurement, participants 
will be instructed to remove shoes and outdoor apparel and gear. Details on how to conduct these 
measurements will be provided to sites.  
8.4.4. 
Vital Signs and Infusion Reaction Monitoring 
The following vital signs will be measured at time points indicated in the Schedule of Events 
(Section 1.3): 
• Temperature  
• Pulse/heart rate 
• Respiratory rate 
• Blood pressure 
Blood pressure and pulse/heart rate measurements should be preceded by at least 5 minutes of rest 
in a quiet setting without distractions (eg, television, cell phones).  
On dosing days, vital signs should be measured at pre-dose and at approximately 15 minutes after 
the start of the infusion, at the end of infusion (approximately 30 minutes), and at 60 minutes after 
the end of the infusion.  
Participants are to be monitored for signs or symptoms of infusion reactions. These include but are 
not limited to fever, chills, headache, nausea, vomiting, infusion-site pain, anaphylaxis, wheezing, 
dyspnea, urticaria, and hypotension. If there are signs or symptoms of infusion reaction in a 
participant during the 60-minute post-infusion observation period, the participant should have vital 
signs assessed and continue to be observed until the reaction is resolved.  
8.4.5. 
 Pregnancy 
Pregnant and lactating women will not be included in the study. Females of childbearing potential 
must have a negative pregnancy test prior to enrolling in the study and will be required to use a 
reliable and effective form of birth control during the study. Male participants will also be required 
to prevent pregnancy in their partners.  At every study visit the sexual activity of participants of 
reproductive age will be re-assessed.  If a participant who was previously sexually inactive 
becomes sexually active, s/he will be counseled about the need to use a reliable and effective form 
of birth control.  Female participants of childbearing potential will also be required to undergo 
urine pregnancy tests at regular intervals including prior to teplizumab administration. A positive 
pregnancy test will result in withholding scheduled drug infusion, and if confirmed, lead to study 
drug discontinuation. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 39 
All pregnancies that are identified during the study must be followed to its termination or delivery, 
and the outcome of each pregnancy must be reported.  The investigator should be informed 
immediately of any pregnancy whether occurring in a female participant or the female partner of 
a male participant.  The investigator should report all pregnancies within the same time frame (24 
hours) as SAEs, using the Pregnancy report form.   
8.5. 
Pharmacokinetics and Immunogenicity 
Blood samples will be obtained to measure teplizumab trough levels and anti-drug antibodies at 
time points indicated in Section 1.3. Instructions for sample processing, handling, and shipping 
will be described in the Laboratory Manual.  
8.6. 
Pharmacodynamics 
Pharmacodynamic parameters are not evaluated in this study. 
8.7. 
Genetics 
Genetic information about TN-10 participants has already been obtained. There are no additional 
genetic studies planned.  
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 40 
9. 
Statistical Considerations 
9.1. 
Statistical Hypotheses 
There is no formal hypothesis to be tested in this study, whose primary objective is to evaluate the 
safety of teplizumab administration in participants of the TN-10 study who have developed clinical 
T1D. For the secondary endpoints, it is proposed that teplizumab treatment will reduce the loss of 
beta cell function (as measured by C-peptide) and will increase the frequency of exhausted T cells, 
TIGIT+KLRG1+CD8+ T cells, compared to baseline (at the start of study drug administration).  
9.2. 
Sample Size Determination 
The sample size will include a maximum of 33 participants who were free of clinical T1D at the 
conclusion of the TN-10 study.  
9.3. 
Populations for Analyses 
The following populations are defined: 
Population 
Description 
Enrolled  
All participants who sign the informed consent and/or assent 
ITT 
All participants who receive at least one dose of the study drug 
Safety 
All participants who receive at least 1 dose of the study drug and 
has at least one post-treatment observation 
 
9.4. 
Statistical Analyses 
The statistical analysis plan will include a more technical and detailed description of the statistical 
analyses described in this section. This section is a summary of the planned statistical analyses of 
the primary and secondary endpoints 
9.4.1. 
Primary Endpoint: Safety  
Safety variables will be presented descriptively. Details will be described in the Statistical Analysis 
Plan (SAP).  
9.4.2. 
Secondary Endpoints 
The effects of teplizumab treatment on the level of C-peptide measured during the MMTT will be 
evaluated and compared to the results with historical control data. The HbA1c levels and insulin 
use will be described descriptively. The frequency of exhausted T cells (CD8+ TIGIT+ KLRG1+ 
T cells), including the effect of anti-drug antibodies, will be described descriptively. 
Additional analyses may be performed and will be specified in the SAP. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 41 
9.4.3. 
Handling Missing/Discontinued Participants  
An intent-to-treat (ITT) approach will be used. Participants will not be replaced.  All data acquired 
prior to termination for the reasons outlined below will be included in the analyses unless the 
participant withdraws consent. Every effort will be made to conduct the Early Termination visit 
with the participant and participants will be followed clinically until, if applicable, all AEs resolve.  
9.5. 
Interim Analyses  
An interim analysis is not planned. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 42 
10. 
Supporting Documentation and Operational Considerations 
10.1. 
Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations 
10.1.1. 
Study-Specific Design Considerations 
Potential participants will be fully informed of the risks and requirements of the study and, during 
the study, participants will be given any new information that may affect their decision to continue 
participation. They will be told that their consent to participate in the study is voluntary and may 
be withdrawn at any time with no reason given and without penalty or loss of benefits to which 
they would otherwise be entitled. Only participants who are fully able to understand the risks, 
benefits, and potential adverse events of the study, and provide their consent voluntarily will be 
enrolled. 
When referring to the signing of the ICF, the terms legal guardian and legally acceptable 
representative refer to the legally appointed guardian of the child with authority to authorize 
participation in research. For each participant, his or her parent(s) (preferably both parents, if 
available) or legally acceptable representative(s), as required by local regulations, must give 
written consent (permission) according to local requirements after the nature of the study has been 
fully explained and before the performance of any study-related assessments. Assent must be 
obtained from children (minors) capable of understanding the nature of the study, typically 
participants 7 years of age and older, depending on the institutional policies. For the purposes of 
this study, all references to participants who have provided consent (and assent as applicable) 
refers to the participants and his or her parent(s) or the participant's legal guardian(s) or legally 
acceptable representative(s) who have provided consent according to this process. Minors who 
assent to a study and later withdraw that assent should not be maintained in the study against their 
will, even if their parents still want them to participate.  
10.1.2. 
Investigator Responsibilities 
The Investigator is responsible for ensuring that the study is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory and 
country-specific requirements. 
Good Clinical Practice is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting studies that involve the participation of human participants. 
Compliance with this standard provides public assurance that the rights, safety, and well-being of 
study participants are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and that the study data are credible. 
10.1.3. 
Regulatory and Ethical Considerations 
Before the start of the study, the Investigator (or Sponsor where required) will provide the IEC/IRB 
with current and complete copies of the following documents (as required by local regulations): 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 43 
• 
Final protocol and, if applicable, amendments 
• 
Sponsor-approved ICF (and any other written materials to be provided to the participants) 
• 
IB (or equivalent information) and amendments/addenda 
• 
Sponsor-approved recruiting materials 
• 
Information on compensation for study-related injuries or payment to participants for 
participation in the study, if applicable 
• 
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented by the IEC/IRB) 
• 
Information regarding funding, name of the Sponsor, institutional affiliations, other 
potential conflicts of interest, and incentives for participants 
• 
Any other documents that the IEC/IRB requests to fulfill its obligation 
This study will be undertaken only after the IEC/IRB has given full approval of the final protocol, 
amendments (if any, excluding the ones that are purely administrative, with no consequences for 
participants, data or study conduct, unless required locally), the ICF, applicable recruiting 
materials, and participant compensation programs, and the Sponsor has received a copy of this 
approval. This approval letter must be dated and must clearly identify the IEC/IRB and the 
documents being approved. 
10.1.4. 
Informed Consent Process 
Each participant and a legally acceptable representative must give written consent according to 
local requirements after the nature of the study has been fully explained. The ICF(s) must be signed 
before performance of any study-related activity. The ICF(s) and assent form that is/are used must 
be approved by both the Sponsor and by the reviewing IEC/IRB and be in a language that the 
participant can read and understand. The informed consent should be in accordance with principles 
that originated in the Declaration of Helsinki, current ICH and GCP guidelines, applicable 
regulatory requirements, and Sponsor policy. 
Before enrollment in the study, the Investigator or an authorized member of the study-site 
personnel must explain to potential participants and their legally acceptable representatives the 
aims, methods, reasonably anticipated benefits, and potential hazards of the study, and any 
discomfort participation in the study may entail. Participants will be informed that their 
participation is voluntary and that they may withdraw consent to participate at any time. They will 
be informed that choosing not to participate will not affect the care the participant will receive for 
the treatment of his or her disease. Participants will be told that alternative treatments are available 
if they refuse to take part and that such refusal will not prejudice future treatment. Finally, they 
will be told that the Investigator will maintain a participant identification register for the purposes 
of long-term follow up if needed and that their records may be accessed by health authorities and 
authorized Sponsor personnel without violating the confidentiality of the participant, to the extent 
permitted by the applicable law(s) or regulations. By signing the ICF/assent, the participant and 
legally acceptable representative are authorizing such access. It also denotes that the participant 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 44 
agrees to allow his or her study physician to recontact the participant for the purpose of obtaining 
consent for additional safety evaluations.  
The participant and legally acceptable representative will be given sufficient time to read the ICF 
and the opportunity to ask questions. After this explanation and before entry into the study, 
assent/consent should be appropriately recorded by means of the participant's and his or her legally 
acceptable representative's personally dated signature. After having obtained the assent/consent, a 
copy of the ICF must be given to the participant and his or her legally acceptable representative. 
If the participant or legally acceptable representative is unable to read or write, an impartial witness 
should be present for the entire informed consent process (which includes reading and explaining 
all written information) and should personally date and sign the assent/ICF after the oral consent 
of the participant or legally acceptable representative is obtained. 
10.1.5. 
Data Protection 
The collection and processing of personal data from participants enrolled in this study will be 
limited to those data that are necessary to fulfill the objectives of the study. The objectives of the 
study and the nature and detail of the personal data to be recorded by the Sponsor as a consequence 
of study participation will be explained to each study participant (or their legally acceptable 
representative) in the ICF and during the consent process. 
These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection laws and regulations. In Europe the Study 
will be conducted in compliance with Regulation (EU) 2016/679 “General Data Protection 
Regulation”. Appropriate technical and organizational measures to protect the personal data 
against unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss 
or alteration must be put in place. Sponsor personnel whose responsibilities require access to 
participants’ personal data shall be approved by the local IEC/IRB and shall agree to keep the 
participants’ personal data confidential. 
The informed assent/consent obtained from the participant and his or her legally acceptable 
representative shall include explicit consent for the processing of personal data and for the 
Investigator/institution to allow direct access to his or her original medical records (source 
data/documents) for study-related monitoring, audit, IEC/IRB review, and regulatory authority 
inspection. This consent also addresses the transfer of the data to other entities and to other 
countries. 
The participant has the right to request access to his or her personal data and the right to request 
rectification of any data that are not correct or complete. Details of which party to contact in respect 
of such requests shall be included in the ICF and in the consent process. Reasonable steps will be 
taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study, and the applicable laws and regulations. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 45 
In addition to these rights, a participant may restrict the processing of incorrect data, request a 
copy of the data or ask for them to be transferred to a third party (portability). A participant can 
also withdraw consent on the data, in which case no further information about the participant will 
be collected from that moment onward. 
Any limitation placed upon the participant’s right to erasure of their personal data from study 
records resulting from the need to conduct the study in compliance to locally applicable regulations 
and laws shall be explained in the ICF and in the consent process. 
Exploratory research is not conducted under standards appropriate for the return of data to 
participants. In addition, the Sponsor cannot make decisions as to the significance of any findings 
resulting from exploratory research. Therefore, exploratory research data will not necessarily be 
returned to participants or Investigators, unless required by law or local regulations. Privacy and 
confidentiality of data generated in the future on stored samples will be protected by the same 
standards applicable to all other clinical data. 
10.1.5.1. Sample and Data Storage 
Samples collected from participants in this study may be stored for up to 15 years or more (or 
according to local regulations) for additional research. Samples can be used to understand the 
effects of teplizumab on Type 1 diabetes, differential drug responders, and to develop tests/assays 
related to teplizumab or other autoimmune conditions. The research may begin at any time during 
the study or the post-study storage period.  
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Participants may withdraw their consent for their samples to be 
stored for research.   
10.1.5.2. Use of Information and Publication 
All information, including but not limited to information regarding teplizumab or the Sponsor's 
operations (eg, patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by the Sponsor to the Investigator and not 
previously published, and any data, including exploratory biomarker research data, generated as a 
result of this study, are considered confidential and remain the sole property of the Sponsor. The 
Investigator agrees to maintain this information in confidence and use this information only to 
accomplish this study and will not use it for other purposes without the Sponsor's prior written 
consent. 
The Investigator must agree to send to the Sponsor for review all manuscripts, abstracts and 
presentations using data from this study prior to their submission for publication. The Sponsor 
reserves the right to delete from such materials any part or parts deemed to be confidential or 
proprietary. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 46 
The Investigator understands that the information developed in the study will be used by the 
Sponsor in connection with the continued development of teplizumab, and thus may be disclosed 
as required to other clinical investigators or regulatory agencies. To permit the information derived 
from the clinical studies to be used, the Investigator is obligated to provide the Sponsor with all 
data obtained in the study. 
The results of the study will be reported in a Clinical Study Report generated by the Sponsor and 
will contain data from all study sites that participated in the study as per protocol. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study will be used to determine a coordinating Investigator. Results of exploratory analyses 
performed after the Clinical Study Report has been issued will be reported in a separate report and 
will not require a revision of the Clinical Study Report. Study participant identifiers will not be 
used in publication of results. Any work created in connection with performance of the study and 
contained in the data that can benefit from copyright protection (except any publication by the 
Investigator as provided for below) shall be the property of the Sponsor as author and owner of 
copyright in such work. 
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the Sponsor shall have the right to publish such primary (multicenter) data and 
information without approval from the Investigator. The Investigator has the right to publish study 
site-specific data after the primary data are published. If an Investigator wishes to publish 
information from the study, a copy of the manuscript must be provided to the Sponsor for review 
at least 60 days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by the Sponsor in 
writing, the Investigator will withhold such publication for up to an additional 60 days to allow for 
filing of a patent application. In the event that issues arise regarding scientific integrity or 
regulatory compliance, the Sponsor will review these issues with the Investigator. The Sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. For multicenter study designs and substudy approaches, secondary results generally 
should not be published before the primary endpoints of a study have been published. Similarly, 
Investigators will recognize the integrity of a multicenter study by not submitting for publication 
data derived from the individual study site until the combined results from the completed study 
have been submitted for publication, within 12 months of the availability of the final data (tables, 
listings, graphs), or the Sponsor confirms there will be no multicenter study publication. 
Authorship of publications resulting from this study will be based on the guidelines on authorship, 
such as those described in the Uniform Requirements for Manuscripts Submitted to Biomedical 
Journals, which state that the named authors must have made a significant contribution to the 
design of the study or analysis and interpretation of the data, provided critical review of the paper, 
and given final approval of the final version. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 47 
10.1.6. 
Registration of Clinical Studies and Disclosure of Results 
The Sponsor will register and disclose the existence of, and the results of clinical studies as 
required by law. 
10.1.7. 
Required Pre-study Documentation 
The following documents must be provided to the Sponsor before shipment of study drug to the 
study site: 
• 
Protocol and amendment(s), if any, signed and dated by the Principal Investigator 
• 
A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, participant compensation programs. This approval must clearly identify the 
specific protocol by title and number and must be signed (or sealed, where appropriate per 
local regulations) by the chairman or authorized designee. 
• 
Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, 
from the IEC/IRB, a general statement may be substituted for this list. If an Investigator or 
a member of the study-site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opinion of the study. 
• 
Regulatory authority approval or notification, if applicable 
• 
Signed and dated statement of Investigator (eg, Form FDA 1572), if applicable 
• 
Documentation of Investigator qualifications (eg, curriculum vitae) 
• 
Completed Investigator financial disclosure form from the Principal Investigator, where 
required 
• 
Signed and dated clinical trial agreement, which includes the financial agreement 
• 
Any other documentation required by local regulations 
 
The following documents must be provided to the Sponsor before enrollment of the first 
participant: 
• 
Completed Investigator financial disclosure forms from all sub-investigators 
• 
Documentation of sub-investigator qualifications (eg, curriculum vitae) 
• 
Name and address of any local laboratory conducting tests for the study, and a dated copy 
of current laboratory normal ranges for these tests, if applicable 
Local 
laboratory 
documentation 
demonstrating 
competence 
and 
test 
reliability 
(eg, accreditation/license), if applicable 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 48 
10.1.8. 
Monitoring 
The Sponsor or designee will use a combination of monitoring techniques (eg, central, remote, or 
on-site monitoring) to monitor this study. 
The Sponsor or designee will perform on-site monitoring visits as frequently as necessary. The 
monitor will record dates of the visits in a study site visit log that will be kept at the study site. The 
first post-initiation visit will be made as soon as possible after enrollment has begun. At these 
visits, the monitor will compare the data entered into the CRF with the source documents 
(eg, hospital/clinic/physician’s office medical records). The nature and location of all source 
documents will be identified to ensure that all sources of original data required to complete the 
CRF are known to the Sponsor and study-site personnel and are accessible for verification by the 
Sponsor study-site contact. If electronic records are maintained at the study site, the method of 
verification must be discussed with the study-site personnel.  
Direct access to source documents (medical records) must be allowed for the purpose of verifying 
that the recorded data are consistent with the original source data. Findings from this review will 
be discussed with the study-site personnel. The Sponsor expects that, during monitoring visits, the 
relevant study-site personnel will be available, the source documents will be accessible, and a 
suitable environment will be provided for review of study-related documents. The monitor will 
meet with the Investigator on a regular basis during the study to provide feedback on the study 
conduct. 
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during these 
remote contacts, study-site personnel will be available to provide an update on the progress of the 
study at the site.  
Central monitoring will take place for data identified by the Sponsor or designee as requiring 
central review. 
10.1.9. 
Data Quality Assurance 
Steps to be taken to ensure the accuracy and reliability of data include the selection of qualified 
investigators and appropriate study sites, review of protocol procedures with the Investigator and 
study-site personnel before the study, and periodic monitoring visits by the Sponsor, and direct 
transmission of clinical laboratory data from a central laboratory into the Sponsor's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples.  
Guidelines for CRF completion will be provided and reviewed with study-site personnel before 
the start of the study.  
Clinical monitors will review CRF for accuracy and completeness during on-site monitoring 
visits and after transmission to the Sponsor; any discrepancies will be resolved with the 
Investigator or designee, as appropriate. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 49 
10.1.10. 
Source Documentation 
At a minimum, source documents consistent in the type and level of detail with that commonly 
recorded at the study site as a basis for standard medical care must be available for the following: 
participant identification, eligibility, and study identification; study discussion and date of signed 
informed consent; dates of visits; results of safety and efficacy parameters as required by the 
protocol; record of all adverse events and follow-up of adverse events; concomitant medication; 
drug receipt/dispensing/return records; study drug administration information; and date of study 
completion and reason for early discontinuation of study drug or withdrawal from the study, if 
applicable.  
The author of an entry in the source documents should be identifiable. 
Specific details required as source data for the study and source data collection methods will be 
reviewed with the Investigator before the study and will be described in the monitoring guidelines 
(or other equivalent document). 
The minimum source documentation requirement for Section 5.1, Inclusion Criteria and Section 
5.2, Exclusion Criteria, that specify a need for documented medical history is the complete history 
of medical notes at the site.  
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by participant interview or other protocol required assessment (eg, physical 
examination, laboratory assessment) and documented in the source documents. 
An electronic source system may be utilized, which contains data traditionally maintained in a 
hospital or clinic record to document medical care (eg, electronic source documents) as well as the 
clinical study-specific data fields as determined by the protocol. 
10.1.11. 
Case Report Form Completion 
Study-specific CRFs are prepared for each participant in electronic format.  
Electronic Data Capture (EDC) will be used for this study. The study data will be transcribed by 
study-site personnel from the source documents onto electronic CRFs (eCRF) via the secure EDC 
system in accordance with the study calendar, and within the timeframe agreed upon between the 
Sponsor and the study site. 
Worksheets may be used for the capture of some data to facilitate completion of the CRF. Any 
such worksheets will become part of the participant's source documents. Data must be entered into 
CRF in English. The CRF must be completed as soon as possible after a participant visit and the 
forms should be available for review at the next scheduled monitoring visit. 
When necessary, queries will be generated in the EDC system. If corrections to a CRF are needed 
after the initial entry into the CRF, this can be done in either of the following ways: 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 50 
• 
Investigator and study personnel can make corrections in the EDC system at their own 
initiative or as a response to a query (from the EDC system). 
• 
Sponsor or Sponsor delegate can generate a query for resolution by the Investigator and 
study-site personnel. 
All CRF entries, corrections, and alterations must be made by the Investigator or authorized study-
site personnel. The Investigator must verify that all data entries in the CRF are accurate and correct. 
Investigator will review, sign, and date completed CRFs at regular intervals as determined by the 
Sponsor. 
10.1.12. 
Record Retention 
In compliance with the ICH/GCP guidelines, the Investigator/institution will maintain all CRF and 
all source documents that support the data collected from each participant, as well as all study 
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a Clinical 
Trial, and all study documents as specified by the applicable regulatory requirement(s). The 
Investigator/institution will take measures to prevent accidental or premature destruction of these 
documents. 
Essential documents must be retained until at least 2 years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications 
in an ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical 
development of the investigational product. These documents will be retained for a longer period 
if required by the applicable regulatory requirements or by an agreement with the Sponsor. It is 
the responsibility of the Sponsor to inform the investigator/institution as to when these documents 
no longer need to be retained. 
If the responsible Investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will accept 
the responsibility. The Sponsor must be notified in writing of the name and address of the new 
custodian. Under no circumstance shall the Investigator relocate or dispose of any study documents 
before having obtained written approval from the Sponsor. 
If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the Investigator/institution must permit access to such reports. 
 
10.1.13. 
Study Completion/Termination 
10.1.14. 
Study Completion/End of Study 
The study will be considered to have completed when the database is locked after the last 
participant’s last visit.  
The Investigator will notify the IRB/IEC when the study has been completed.  
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 51 
10.1.15. 
Study Termination 
The Sponsor reserves the right to close a study site or terminate the study at any time for any reason 
at the sole discretion of the Sponsor. Study sites will be closed upon study completion. A study 
site is considered closed when all required documents and study supplies have been collected and 
a study-site closure visit has been performed. 
The Investigator may initiate study-site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by the Sponsor or Investigator may include but are not 
limited to: 
• 
Failure of the Investigator to comply with the protocol, the requirements of the IEC/IRB 
or local health authorities, the Sponsor's procedures, or GCP guidelines 
• 
Inadequate recruitment of participants by the Investigator  
Discontinuation of further study drug development 
10.1.16. 
On-Site Audits 
Representatives of the Sponsor's clinical quality assurance department or designee may visit the 
study site at any time during or after completion of the study to conduct an audit of the study in 
compliance with regulatory guidelines and company policy. These audits will require access to all 
study records, including source documents, for inspection. Participant privacy must, however, be 
respected. The Investigator and study-site personnel are responsible for being present and available 
for consultation during routinely scheduled study-site audit visits conducted by the Sponsor or its 
designees.  
Similar auditing procedures may also be conducted by agents of any regulatory body, either as 
part of a national GCP compliance program or to review the results of this study in support of a 
regulatory submission. The Investigator should immediately notify the Sponsor if he or she has 
been contacted by a regulatory agency concerning an upcoming inspection. 
 
 
 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 52 
10.2. 
Appendix 2: Clinical Laboratory Tests Performed Locally 
The following clinical laboratory assessments will be performed locally during the study as 
described in the Schedule of Events (Section 1.3): 
• 
Chemistry (sodium, potassium, chloride, CO2, glucose, BUN, creatinine) 
• 
Liver function tests (ALT, AST, LDH, alkaline phosphatase, total protein, albumin, total 
and direct bilirubin). Prior to each infusion, MMTT will be run locally in participants with 
Gilbert’s syndrome. 
• 
Hematology (complete blood count with differential and platelets) 
• 
HbA1c 
• 
Purified protein derivative (PPD) or IGRA test for TB 
• 
Urine pregnancy test for women of childbearing potential (WOCBP) 
• 
Antibodies to HIV, hepatitis B (anti-hepatitis B core antibody, hepatitis B surface antigen), 
hepatitis C (HCV) 
• 
Cytomegalovirus antibodies (CMV IgG and IgM).,  
• 
Epstein-Barr virus antibodies (EBV IgG, IgM and EBNA). The Investigator must review 
the laboratory results, document this review, and record any clinically relevant changes 
occurring during the study in the AE section of the CRF. The laboratory reports must be 
filed with the source documents. 
 
 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 53 
10.3. 
Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow-up, and Reporting 
10.3.1. 
Definition of AE 
AE Definition 
• An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study intervention, whether or not considered 
related to the study intervention. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study intervention. 
• Hypoglycemia and hyperglycemia will be reported as adverse events only in the case 
of requiring the assistance of others due to loss of consciousness or diabetic 
ketoacidosis (DKA). 
Unexpected AE: 
• An adverse event is considered unexpected when the nature (specificity) or severity of 
the event is not consistent with the risks described in the Investigator’s Brochure or the 
informed consent document. 
 
Events Meeting the AE Definition 
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the 
medical and scientific judgment of the investigator (i.e., not related to progression of 
underlying disease). 
• Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming 
intent. Such overdoses should be reported regardless of sequelae. 
 
 
 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 54 
 
Events NOT Meeting the AE Definition 
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition. 
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
10.3.2. 
Definition of SAE 
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (e.g., hospitalization for signs/symptoms of the disease under study, death due to 
progression of disease). 
An SAE is defined as any untoward medical occurrence that, at any dose: 
a. Results in death 
b. Is life-threatening 
The term 'life-threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe. 
c. 
Requires inpatient hospitalization or prolongation of existing hospitalization 
• In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary, the 
AE should be considered serious. 
• Hospitalization for elective treatment of a pre-existing condition that did not worsen 
from baseline is not considered an AE. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 55 
d. Results in persistent disability/incapacity 
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. 
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (e.g., sprained ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption. 
e. 
Is a congenital anomaly/birth defect 
f. 
Other situations: 
• Medical or scientific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize the 
participant or may require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definition. These events should usually be considered 
serious. 
• 
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug dependency or 
drug abuse. 
10.3.3. 
Definition of AESI 
The following types of AEs are considered AESIs:  
• All infections: viral, fungal, bacterial 
• Acute mononucleosis-like illness (eg, fever, pharyngitis, lymphadenopathy) 
• CMV viremia defined using DNA PCR testing and >10,000 copies per mL serum or 106 
cells 
• EBV viremia defined using DNA PCR testing and >10,000 copies per mL serum or 106 
cells 
• Herpes zoster or other conditions related to VZV 
• Primary infection with or reactivation of latent tuberculosis  
• Infections requiring IV antibiotic treatment 
• Demyelinating diseases 
• Malignancies including lymphomas 
• Severe hypoglycemic episodes that require assistance by another individual through the 
administration of oral or parenteral dextrose, glucagon or intervention 
• ≥ Grade 3 liver function abnormalities (AST, ALT, bilirubin) 
• ≥ Grade 3 thrombocytopenia (platelet counts less than 50,000/µL) 
• ≥ Grade 3 allergic/hypersensitivity reaction (anaphylaxis)  
• ≥ Grade 3 Rash 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 56 
• ≥ Grade 3 cytokine-release syndrome  
• ≥ Grade 4 neutropenia (<500 PMN/µL on 2 consecutive evaluations performed on 
different days) 
10.3.4. 
Reporting and Follow-Up of AE and/or SAE 
AE and SAE Reporting 
Timely, accurate, and complete reporting and analysis of safety information from clinical studies 
are crucial for the protection of participants, Investigators, and the Sponsor, and are mandated 
by regulatory agencies worldwide. The Sponsor has established Standard Operating Procedures 
in conformity with regulatory requirements worldwide to ensure appropriate reporting of safety 
information; all clinical studies conducted by the Sponsor or its affiliates will be conducted in 
accordance with those procedures. 
The determination of seriousness, severity and causality must be made by the physician 
Investigator who is qualified to review adverse event information, provide a medical 
evaluation of adverse events, and classify adverse events based upon medical judgment. 
An adverse event is any untoward medical occurrence in a clinical study participant from the 
time they formally agree to participate in the study (eg, by providing informed consent/assent) 
through their last study contact (eg, last visit or status update). An adverse event does not 
necessarily have a causal relationship with the study drug. An adverse event can therefore be 
any unfavorable and unintended sign (including an abnormal finding), symptom, or disease 
temporally associated with the use of a study drug (investigational or non-investigational 
product), whether or not related to that study drug (investigational or non-investigational 
product).  
This includes any occurrence that is new in onset or aggravated in severity or frequency from 
the baseline condition, or abnormal results of diagnostic procedures, including laboratory test 
abnormalities. 
A treatment-emergent adverse event (TEAE) is defined as an AE that occurs after the first 
dose of study drug administration (Day 1) through the end of the study or early termination. 
The Investigator must follow all SAEs (including serious AESIs) until resolution even if this 
extends beyond the study-reporting period. Resolution of a SAE is defined as the return to pre- 
treatment status or stabilization of the condition with the expectation that it will remain chronic. 
At any time after completion of the study, if an Investigator becomes aware of a serious adverse 
event that s/he suspects is related to study drug, the Investigator should report the event to the 
Pharmacovigilance contact. 
These events will be captured on the CRF and reported to the Sponsor as described in Section 
8.4.1.1. Any event that meets serious adverse event criteria will be reported to the Sponsor 
within the appropriate timeline as described in Section 8.4.1.4.  
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 57 
Events will be assessed and reported consistent with the ICH Guideline for Good Clinical 
Practice and per the guidance of the DHHS Office for Human Research Protections (OHRP).   
Event outcome and other follow-up information regarding the treatment and resolution of the 
event will be obtained and reported when available, if not known at the time the event is 
initially reported.  The follow-up information should contain sufficient detail to allow for a 
complete medical assessment of the case and an independent determination of possible 
causality.  
AESIs should be reported according to the requirements for SAEs.  
Assessment of Severity 
An assessment of severity grade for each AE will be made by the site Investigator according to 
the criteria set forth in the National Cancer Institute’s Common Terminology Criteria for 
Adverse Events Version 5.0.  This document (referred to herein as the “CTCAE V5.0”) provides 
a common language to describe levels of severity, to analyze and interpret data, and to articulate 
the clinical significance of all AEs. The Investigator should use clinical judgment in assessing 
the severity of events not directly experienced by the participant (eg, laboratory abnormalities). 
Adverse events will be graded according to National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) version 5.0: 
• 
Grade 1 = Mild adverse event. 
• 
Grade 2 = Moderate adverse event. 
• 
Grade 3 = Severe adverse event.  
• 
Grade 4 = Life-threatening or disabling adverse event. 
• 
Grade 5 = Death  
 
Assessment of Causality 
The Investigator is required to provide an assessment of causality or relationship of adverse 
events to the study drug based on 1) temporal relationship of the event to the administration of 
study drug; 2) whether an alternative etiology has been identified; and 3) biological plausibility. 
The causality assessment categories that will be used for this study are described below. 
Causality assessments considered not related to study drug: 
• 
Unrelated: The event is related to an etiology other than the study drug (the alternative 
etiology must be documented in the participant’s medical record). 
• 
Unlikely: The event is unlikely to be related to the study drug and likely to be related to 
factors other than study drug. 
Causality assessments considered related to study drug: 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 58 
• 
Possible: There is an association between the event and the administration of the study 
drug and there is a plausible mechanism for the event to be related to study drug; but 
there may also be alternative etiology, such as characteristics of the participant’s clinical 
status or underlying disease. 
• 
Probable: There is an association between the event and the administration of study drug, 
a plausible mechanism for the event to be related to the study drug and the event could 
not be reasonably explained by known characteristics of the participant’s clinical status 
or an alternative etiology is not apparent. 
Definite: There is an association between the event and the administration of study drug, a 
plausible mechanism for the event to be related to the study drug and causes other than the 
study drug have been ruled out and/or the event re-appeared on re-exposure to the study drug. 
 
 
 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 59 
10.4. 
Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information 
Definitions: 
Woman of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile (see below). 
 
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study intervention, additional evaluation should be considered. 
Women in the following categories are not considered WOCBP 
1. Premenarchal 
2. Premenopausal female with 1 of the following: 
• Documented hysterectomy 
• Documented bilateral salpingectomy 
• Documented bilateral oophorectomy 
 
For individuals with permanent infertility due to an alternate medical cause other than the 
above, (e.g., mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry. 
Note: Documentation can come from the site personnel’s: review of the participant’s medical 
records, medical examination, or medical history interview. 
3. Postmenopausal female: 
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. 
o A high follicle stimulating hormone (FSH) level in the postmenopausal range may be 
used to confirm a postmenopausal state in women not using hormonal contraception or 
hormonal replacement therapy (HRT). However, in the absence of 12 months of 
amenorrhea, confirmation with more than one FSH measurement [insert threshold if 
required (>40 IU/L or mIU/mL) or remove to allow for flexibility with different local 
thresholds for defining postmenopausal state] is required.  
• Females on HRT and whose menopausal status is in doubt will be required to use one of 
the non-estrogen hormonal highly effective contraception methods if they wish to continue 
their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation 
of postmenopausal status before study enrollment. 
Male participants with partners who become pregnant 
• The investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This 
applies only to male participants who receive [study intervention]. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 60 
• After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the investigator will record pregnancy information on the appropriate form and 
submit it to the sponsor within [24 hours] of learning of the partner’s pregnancy. The 
female partner will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to the sponsor. 
Generally, the follow-up will be no longer than 6 to 8 weeks following the estimated 
delivery date. Any termination of the pregnancy will be reported regardless of fetal status 
(presence or absence of anomalies) or indication for the procedure.  
Female Participants who become pregnant 
• 
The investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study.  The initial information will be recorded 
on the appropriate form and submitted to the sponsor within [24 hours] of learning of a 
participant's pregnancy.  
• 
The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow-up information on the participant and the neonate and the 
information will be forwarded to the sponsor. Generally, follow-up will not be required for 
longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy 
will be reported, regardless of fetal status (presence or absence of anomalies) or indication 
for the procedure. 
• 
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication 
or elective termination of a pregnancy for medical reasons will be reported as an AE or 
SAE.  
• 
A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurring 
at >22 weeks gestational age) is always considered to be an SAE and will be reported as 
such.  
• 
Any post-study pregnancy related SAE considered reasonably related to the study 
intervention by the investigator will be reported to the sponsor. While the investigator is 
not obligated to actively seek this information in former study participants, he or she may 
learn of an SAE through spontaneous reporting. 
• 
Any female participant who becomes pregnant while participating in the study [will 
discontinue study intervention or be withdrawn from the study] OR [may request 
continuation of study intervention. 
 
 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 61 
10.5. 
Appendix 5: Abbreviations 
ADA 
American Diabetes Association 
AE 
adverse event 
AESI 
adverse event of special interest 
ALT 
alanine aminotransferase 
AST 
aspartate aminotransferase 
AUC 
area under the time-versus-concentration curve 
BP 
blood pressure 
BSA 
body surface area 
BUN 
blood urea nitrogen 
CBC 
complete blood count 
CD 
cluster of differentiation  
CMV 
cytomegalovirus 
CRF 
case report form(s) (paper or electronic as appropriate for this study) 
CRS 
cytokine-release syndrome 
CTCAE 
Common Terminology Criteria for Adverse Events 
DCCT 
Diabetes Control and Complications Trial 
DKA 
diabetic ketoacidosis 
DNA 
deoxynucleic acid 
DPT-1 
Diabetes Prevention Trial – Type 1 
EBNA 
Epstein Barr nuclear antigen 
EBV 
Epstein-Barr virus 
EDC 
electronic data capture 
ENDIT 
European Nicotinamide Diabetes Intervention Trial 
ET 
early termination 
Fc 
fragment crystallizable region of an antibody/immunoglobulin molecule 
FcR 
receptor binding to the Fc component of antibody molecules 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
HbA1c 
hemoglobin A1c 
HBV 
hepatitis B virus 
HCV 
hepatitis C virus 
HIV 
human immunodeficiency virus 
HR 
heart rate 
IB 
Investigator Brochure 
ICF 
informed consent form 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 62 
ICH 
International Council for Harmonisation 
IEC 
Independent Ethics Committee 
Ig 
immunoglobulin 
IGRA 
interferon gamma release assay 
IHSG 
International Hypoglycaemia Study Group 
IL 
interleukin  
IRB 
Institutional Review Board 
ITT 
intent to treat 
IV 
intravenous(ly) 
KD 
kilodalton 
LDH 
lactate dehydrogenase 
LFT 
liver function test 
mAb 
monoclonal antibody 
MedDRA 
Medical Dictionary for Regulatory Activities 
MHC 
major histocompatibility complex 
MMTT 
mixed meal tolerance test 
NAb 
neutralizing antibody 
NCI 
National Cancer Institute 
NSAID 
nonsteroidal anti-inflammatory drug 
PBMC 
peripheral blood mononuclear cell 
PCR 
polymerase chain reaction 
PK 
pharmacokinetic(s) 
PMN 
polymorphonuclear leukocyte 
PPD 
purified protein derivative 
PVC 
polyvinyl chloride 
RNA 
ribonucleic acid 
RR 
respiratory rate 
SAE 
serious adverse event 
SAP 
Statistical Analysis Plan 
SD 
standard deviation 
SUSAR 
suspected unexpected serious adverse reaction 
TEAE 
treatment-emergent adverse event 
T1D 
type 1 diabetes 
TN-10 
Anti-CD3 Monoclonal Antibody (Teplizumab) for Prevention of Diabetes in Relatives At-Risk 
for Type 1 Diabetes Mellitus Trial 
TB 
tuberculosis 
TCR 
T cell receptor 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 63 
TEAE 
treatment-emergent adverse event 
U 
unit 
ULN 
upper limit of normal range 
VZV 
varicella zoster virus 
WBC 
white blood cell  
ZnT8 
zinc transporter 8 
 
 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 64 
11. 
References
Atkinson MA. ADA Outstanding Scientific Achievement Lecture 2004. Thirty years of 
investigating the autoimmune basis for type 1 diabetes: why can’t we prevent or reverse this 
disease? Diabetes. 2005;54(5):1253-63. 
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The 
effect of intensive treatment of diabetes on the development and progression of long-term 
complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86. 
EURODIAB ACE Study Group. Variation and trends in incidence of childhood diabetes in 
Europe. Lancet. 2000;355(9207):873-876.Gale EA, Bingley PJ, Emmett CL, Collier T, 
European 
Nicotinamide 
Diabetes 
Intervention 
Trial 
(ENDIT) 
Group. 
European 
Nicotinamide 
Diabetes Intervention Trial (ENDIT): a randomised controlled trial of 
intervention before the onset of type 1 diabetes. Lancet 2004;363(9413):925-931. 
Hagopian W, Ferry RJ Jr, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 
diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 
2013;62(11):3901-3908. 
Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 
1 diabetes mellitus. N Engl J Med. 2002;346(22):1692-1698. 
Herold KC, Gitelman SE, Umest M et al.  A single course of anti-CD3 monoclonal antibody 
hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at 
least 2 years after onset of type 1 diabetes. Diabetes. 2005;54(6):1-7. 
Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-
peptide responses in patients with new-onset type 1 diabetes in a randomized controlled 
trial: metabolic and immunologic features at baseline identify a subgroup of responders. 
Diabetes. 2013(a);62(11):3766-3774. 
Herold KC, Gitelman SE, Willi SM, et al. Teplizumab treatment may improve C-peptide 
responses in participants with type 1 diabetes after the new-onset period: a randomised 
controlled trial. Diabetologia. 2013(b);56(2):391-400. 
Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at 
Risk for Type 1 Diabetes. N Engl J Med. 2019;381(7):603-613. 
Imperatore G, Mayer-Davis EJ, Orchard TJ, Zhong VW. Prevalence and Incidence of Type 1 
Diabetes Among Children and Adults in the United States and Comparison With Non-U.S. 
Countries. Chapter 2 in Diabetes in America, 3rd ed. Cowie CC, Casagrande SS, Menke A, Cissell 
MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, 
Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, Eds. 
Bethesda, MD, National Institutes of Health, NIH Pub No. 17-1468, 2018.  http://
www.niddk.nih.gov/about-niddk/strategic-plans-reports/diabetes-in-america-3rd-edition. 
Accessed on September 28, 2019.  
International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 mmol/L (54 
mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the 
American Diabetes Association and the European Association for the Study of Diabetes. 
Diabetes Care. 2016;dc162215. 
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
Provention Bio, Inc. 
 65 
Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy 
in new-onset type 1 diabetes. N Engl J Med. 2005 Jun 23;352(25):2598-2608. 
Kuhtreiber WM, Washer SL, Hsu E, et al. Low levels of C-peptide have clinical significance for 
established Type 1 diabetes. Diabet Med. 2015 Oct;32(10):1346-1353. 
Lachin JM, McGee P, Palmer JP; DCCT/EDIC Research Group. Impact of C-peptide preservation 
on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. 
Diabetes. 2014;63(2):739-748. 
Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort 
with type 1 diabetes, 2008-2010. JAMA. 2015;313(1):37-44. 
Long SA, Thorpe J, DeBerg HA, et al. Partial exhaustion of CD8 T cells and clinical response to 
teplizumab in new-onset type 1 diabetes. Sci Immunol. 2016;1(5). pii: eaai7793. 
Mach H, Middaugh CR, Lewis RV. Statistical determination of the average values of the 
extinction coefficients of tryptophan and tyrosine in native proteins. Anal Biochem. 
1992;200(1):74-80. 
Rawshani A, Sattar N, Franzén S, et al. Excess mortality and cardiovascular disease in young 
adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort 
study. Lancet. 2018;392(10146):477-486. 
Riley WJ, Maclaren NK, Krischer J, et al. A prospective study of the development of diabetes in 
relatives of patients with insulin-dependent diabetes. N Engl J Med. 1990;323(17):1167-1172. 
Sherr J, Sosenko J, Skyler JS, Herold KC. Prevention of type 1 diabetes: the time has come. Nat 
Clin Pract Endocrinol Metab. 2008;4(6):334-343.  
Sherry N, Hagopian W, Ludvigsson J, et al., Protégé Trial Investigators. Teplizumab for treatment 
of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled 
trial. Lancet. 2011;378(9790):487-497. 
Sorensen JS, Johannesen J, Pociot F, et al. Residual β-cell function 3–6 years after onset of type 
1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care. 
2013;36(11):3454-3459. 
Sosenko JM, Palmer JP, Greenbaum et al. Patterns of metabolic progression to type 1 diabetes 
in the Diabetes Prevention Trial-Type 1. Diabetes Care. 2006;29(3):643-649. 
Steffes MW, Sibley S, Jackson M, Thomas W.  Beta-cell function and the development of 
diabetes-836.
related complications in diabetes control and complications trial.  Diabetes Care.  
2003;26(3):832-836.
VV-CLIN-0666755 1.0


CONFIDENTIAL 
Protocol PRV-031-002, version 1.0 
 
Provention Bio, Inc. 
 66 
INVESTIGATOR AGREEMENT 
I have read this protocol and agree that it contains all necessary details for carrying out this study. 
I will conduct the study as outlined herein and will complete the study within the time designated. 
I will provide copies of the protocol and all pertinent information to all individuals responsible to 
me who assist in the conduct of this study. I will discuss this material with them to ensure that they 
are fully informed regarding the study drug, the conduct of the study, and the obligations of 
confidentiality. 
Coordinating Investigator (where required): 
Name (typed or printed):  
Institution and Address: 
 
 
 
 
 
Signature: 
 
Date: 
 
 
 
 
(Day Month Year) 
 
Principal (Site) Investigator: 
Name (typed or printed):  
Institution and Address: 
 
 
 
 
 
Telephone Number: 
 
Signature: 
 
Date: 
 
 
 
 
(Day Month Year) 
Sponsor's Responsible Medical Officer: 
Name (typed or 
printed): 
Organization: 
Provention Bio, Inc 
Signature: 
 
Date: 
 
 
 
 
(Day Month Year) 
 
Note: If the address or telephone number of the Investigator changes during the course of the 
study, written notification will be provided by the Investigator to the Sponsor, and a protocol 
amendment will not be required. 
 
VV-CLIN-0666755 1.0

SAP_001.pdf: 
  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 1 of 21
SAP template CT
Effective: 01MAR2018
STATISTICAL ANALYSIS PLAN
Study title
Study No/Code 
Phase
Sponsor 
Document version 
Document date
NCT
An Open-Label Study to Evaluate the Safety of 
Teplizumab (PRV-031) in At-Risk Relatives Who Develop 
Type 1 Diabetes
PRV-031-002
II
Provention Bio, Inc.
V1.0
21FEB2024
NCT04270942 
This study was conducted in accordance with GCP.
Property of Provention Bio, Inc.
This statistical analysis plan and all the information relating to it is confidential and proprietary 
property of Provention Bio, Inc. and may not be reproduced, published or disclosed to others 
without a written authorisation of Provention Bio, Inc.
VV-CLIN-0674120 1.0


 PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 2 of 21
SAP template CT
Effective: 01MAR2018
TABLE OF CONTENTS
SIGNATURE PAGE – COMPANY...........................................................................................................4
SIGNATURE PAGE – CLIENT ................................................................................................................5
LIST OF ABBREVIATIONS.....................................................................................................................6
1
INTRODUCTION...........................................................................................................................7
2
STUDY OBJECTIVES AND ENDPOINTS ..........................................................................................7
3
STUDY TYPE AND DESIGN............................................................................................................8
4
RANDOMIZATION .......................................................................................................................8
5
STATISTICAL HYPOTHESES...........................................................................................................9
6
ESTIMATION OF SAMPLE SIZE .....................................................................................................9
7
STATISTICAL METHODS ...............................................................................................................9
7.1
ANALYSIS SETS..................................................................................................................9
7.2
GENERAL STATISTICAL CONSIDERATIONS ..................................................................................9
7.2.1 Definition of derived variables.....................................................................................10
7.2.2 Imputing missing values..............................................................................................10
7.3
DISPOSITION OF PARTICIPANTS .............................................................................................11
7.4
DEMOGRAPHIC AND BASELINE CHARACTERISTICS AND MEDICAL HISTORY ....................................11
7.5
PRIOR AND CONCOMITANT MEDICATIONS .............................................................................12
7.6
EXTENT OF EXPOSURE AND COMPLIANCE ...............................................................................12
7.7
ANALYSIS OF SAFETY AND TOLERABILITY................................................................................12
7.7.1 Adverse events.............................................................................................................12
7.7.2 Laboratory safety variables..........................................................................................16
7.7.3 Vital signs and anthropomorphic measurements..........................................................17
7.7.4 Physical examination ...................................................................................................17
7.7.5 Pregnancy....................................................................................................................17
7.7.6 Epstein-Barr virus (EBV) antibodies and cytomegalovirus (CMV) antibodies.................17
7.8 
OTHER ANALYSES .............................................................................................................18
7.8.1 Mixed Meal Tolerance Test (MMTT).............................................................................18
7.8.2 HbA1c (%)....................................................................................................................18
7.8.3 Exogenous Insulin ........................................................................................................18
7.8.4 Insulin Discontinuation Criteria ....................................................................................18
7.8.5 Severe Hypoglycemic Episodes .....................................................................................19
7.8.6 Pharmacokinetics and Immunogenicity........................................................................19
7.8.7 Mechanistic Assessments.............................................................................................19
7.9 
INTERIM ANALYSIS ............................................................................................................20
7.10 
CHANGES IN THE STATISTICAL PLANS FROM THOSE PRESENTED IN THE STUDY PROTOCOL (IF APPLICABLE)20
7.11 
EXECUTION OF STATISTICAL ANALYSES ...................................................................................20
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 3 of 21
SAP template CT
Effective: 01MAR2018
8 
HARDWARE AND SOFTWARE....................................................................................................20
9 
REFERENCES ..............................................................................................................................20
10 APPENDICES ..............................................................................................................................20
11 DOCUMENT HISTORY ................................................................................................................20
VV-CLIN-0674120 1.0


 PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 4 of 21
SAP template CT
Effective: 01MAR2018
SIGNATURE PAGE – COMPANY
This statistical analysis plan was prepared and approved by:
Name of author:
Title:
, IQVIA Biotech
Signature:
VV-CLIN-0674120 1.0


 PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 5 of 21
SAP template CT
Effective: 01MAR2018
SIGNATURE PAGE – CLIENT
The statistical analysis plan was reviewed and approved by:
Name of client’s 
representative:
Title:
 
Company:
Provention Bio, Inc.
Signature:
Name of client’s 
representative:
Title:
Company:
Sanofi
Signature:
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 6 of 21
SAP template CT
Effective: 01MAR2018
LIST OF ABBREVIATIONS
AE
Adverse event
AESI
Adverse event of special interest
AUC
Area under the time-versus-concentration curve
BMI
Body Mass Index
BSA
Body Surface Area
CMV
Cytomegalovirus
CTCAE
NCI Common Terminology Criteria for Adverse Events
EBV
Epstein-Barr Virus
GADA
Glutamic Acid Decarboxylase (GAD65)
HbA1c
Hemoglobin A1c
IA-2
Islet Antigen 2
IgG
Immunoglobulin G
IgM
Immunoglobulin M
IV
Intravenous(ly)
MedDRA
Medical dictionary for regulatory activities
mIAA
Major Islet Autoantibodies against Insulin
MMTT
Mixed meal tolerance test
PK
Pharmacokinetics
qPCR
Quantitative Polymerase Chain Reaction
SAE
Serious adverse event
SAP
Statistical analysis plan
SAS®
Statistical Analysis System
SD
Standard deviation
T1D
Type 1 diabetes
TEAE
Treatment emergent adverse event
TN-10
Anti-CD3 Monoclonal Antibody (Teplizumab) for Prevention of Diabetes 
in Relatives At-Risk for Type 1 Diabetes Mellitus Trial 
WHODrug
World health organization drug dictionary
ZnT8
Zinc Transporter 8
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 7 of 21
SAP template CT
Effective: 01MAR2018
1
INTRODUCTION
This is a statistical analysis plan (SAP) for study PRV-031-002 which is based on the final study 
protocol version 1.0 (dated 02DEC2019). This SAP describes the statistical analyses which will be 
presented in the clinical study report.
The SAP is a supplement to the study protocol, which should be referred to for additional details on 
study objectives, endpoints, study design, study conduct, and other operational aspects of the study. 
2
STUDY OBJECTIVES AND ENDPOINTS
Objectives and Endpoints
Objectives
Endpoints
Primary
x
To evaluate the safety and 
tolerability of teplizumab treatment, 
administered intravenously (IV) to 
participants in the TN-10 trial who 
have developed T1D.
x
Incidence of treatment-emergent adverse 
events (TEAEs), adverse events of special 
interest (AESIs), and serious adverse 
events (SAEs) 
Secondary
x
To evaluate the pharmacokinetics 
(PK) and immunogenicity of 
teplizumab 
x
Levels of teplizumab in the serum and anti-
drug antibodies 
x
To evaluate whether teplizumab 
treatment reduces the loss of β 
cells, over 78 weeks (18 months), 
in individuals with recent diagnosis 
of T1D. 
x
The area under the time-versus-
concentration curve (AUC) of C-peptide 
after a 4-hour (4h) mixed-meal tolerance 
test (MMTT), a measure of endogenous 
insulin production and β cell function, over 
78 weeks 
x
To evaluate key clinical parameters 
of diabetes management, including 
insulin use, hemoglobin A1c 
(HbA1c), and clinically important 
hypoglycemic episodes over 78 
weeks 
x
HbA1c levels; insulin use, defined as a daily 
average dose in units per kilogram per day 
(U/kg/day); and frequency of clinically 
important hypoglycemic episodes over 78 
weeks
x
To evaluate whether treatment with 
teplizumab increases the frequency 
of exhausted T cells
x
Frequency of CD8+ TIGIT+ KLRG1+ T cells 
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 8 of 21
SAP template CT
Effective: 01MAR2018
3
STUDY TYPE AND DESIGN
This is a single-arm, multi-center, open-label clinical trial. Teplizumab-treated and placebo 
participants from the TN-10 trial who develop clinical type 1 diabetes after the conclusion of that 
trial, are eligible to enroll and receive teplizumab treatment in this open-label study within one year 
of Stage 3 clinical T1D diagnosis.
Up to 30 participants may be enrolled in this study.
All participants will receive a 12-day course of teplizumab given through a daily IV infusion. The 
participant’s dosing course will be based on the body surface area (BSA), in m2, calculated on 
Study Day 1. The drug dosing is as follows:
x
Day 1: 106 μg/m2
x
Day 2: 425 μg/m2
x
Days 3-12: 850 μg/m2
Participants will have a screening period of up to 4 weeks, a treatment period of 12 days, and a 
follow-up period of up to 78 weeks (18 months) from the first dose of treatment. The study schema 
is shown in Figure 1.
Figure 1     Study Schema
4
RANDOMIZATION
Randomization is not applicable for this open-label study.
Teplizumab Course:
 Day 1: 106 μg/m2 IV
 Day 2: 425 μg/m2 IV
 Days 3-12: 850 μg/m2 IV
Screen
Observation Phase
Week:
-4
0
MMTT:
26
78
52
4h
4h
4h
4h
Baseline
X
Participants from
TN-10 study
 Diagnosis of T1D
 Treatment within 1
year of diagnosis
HbA1c/
Insulin use:
X
X
12
X
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 9 of 21
SAP template CT
Effective: 01MAR2018
5
STATISTICAL HYPOTHESES
There is no formal statistical hypothesis to be tested in this study.  The primary objective is to 
evaluate the safety of teplizumab administration in participants of the TN-10 trial who have 
developed clinical T1D. For the secondary endpoints, it is proposed that teplizumab treatment will 
reduce the loss of beta cell function (as measured by C-peptide) and will increase the frequency of 
exhausted T cells, TIGIT + KLRg1 + CD8 + T cells, compared to baseline (at the start of study drug 
administration).
6
ESTIMATION OF SAMPLE SIZE
Sample size calculation was not based upon any formal statistical considerations. The sample size 
will include a maximum of 30 participants who develop clinical T1D after the conclusion of the TN-
10 trial.
7
STATISTICAL METHODS
7.1
Analysis sets
The Enrolled analysis set will be comprised of all participants who sign the informed consent and/or 
assent.
The Safety analysis set will be comprised of all participants who receive at least one dose of the 
study drug.
The PK analysis set will be comprised of participants from the Safety analysis set who have at least 
one evaluable sample for PK analysis. 
The Immunogenicity analysis set will be comprised of participants from the Safety analysis set who 
have at least one evaluable sample for Immunogenicity analysis. 
7.2
General statistical considerations
No inferential statistical analysis will be performed. Only descriptive statistics will be presented. Data 
listings will provide both the participant identification number and treatment arm from the TN-10 
trial as well as the participant identifier in the TN-10 Extension study. Summary tables will, in general, 
have a Total column only; however, where noted, tables will be presented by prior treatment 
(teplizumab or placebo) in the parent TN-10 trial. 
Continuous variables and the respective changes from baseline (if applicable) will be summarized by 
assessment time using the number of observations (n), mean, standard deviation (SD), median and 
minimum and maximum. Unless otherwise specified, categorical variables will be presented by the 
number of participants and percentages based on the respective analysis set.
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 10 of 21
SAP template CT
Effective: 01MAR2018
Decimal places for summary statistics are given in Table 2. For derived variables such as BMI, value 
should be rounded to 1 decimal place and the same rules should be applied as in Table 1.
Table 1     Decimal places for summary statistics of continuous variables
Statistic
Number of digits
Minimum, maximum
Same as original data
Mean, median
1 more than in original data
SD
2 more than in original data
Frequencies (%)
1 decimal place
7.2.1
Definition of derived variables
Definition of Baseline
Unless otherwise specified, the baseline value will be taken as the last non-missing value available 
prior to the start of dosing with teplizumab.
Definition of Study Day
In data listings, the day of the first dose of teplizumab administration will be designated Study Day 
1. The day before the day of the first dose of teplizumab administration will be designated Study
Day -1.
Body Mass Index
Body mass index (BMI) is calculated using the formula: 
ꢀꢁꢂꢃꢄꢅ
ꢆꢇꢈ=
ꢉꢊꢋꢅℎꢌ(ꢄꢅ)
[ℎꢊꢋꢅℎꢌ(ꢆ) ∙ℎꢊꢋꢅℎꢌ(ꢆ)]
Body Surface Area
Body Surface Area (m2) is calculated using the Mosteller formula:
ꢀꢍꢎ(ꢆꢇ) = ꢏ[ꢐꢊꢋꢅℎꢌ(ꢑꢆ)ꢒꢓꢊꢋꢅℎꢌ(ꢄꢅ)]
3600
7.2.2
Imputing missing values
In general, missing values will not have any imputation, with some exceptions noted below: 
Adverse Events, Prior Medications and Concomitant Medications
Partial dates for adverse event start/stop or concomitant medication start/stop will not be imputed 
in data listings. However, information from partial adverse event start dates may be used to 
determine whether an adverse event is treatment emergent. Information from partial start dates
may be used to determine between prior medications and concomitant medications.
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 11 of 21
SAP template CT
Effective: 01MAR2018
7.3
Disposition of participants
The number of participants enrolled will be tabulated as well as the number and percentage of 
enrolled participants who are in the Safety, PK, and Immunogenicity analysis sets.
The number and percentage of participants in the Safety analysis set who discontinue study drug 
early and reason for early discontinuation of study drug [adverse event, Investigator decision, 
participant decision, other] will be tabulated.
The number and percentage of participants in the Safety analysis set who discontinue the study
early and complete the study will be tabulated along with reasons for early study discontinuation
[lost to follow-up, withdrawal of consent/assent, death, Investigator or Sponsor judgement, 
pregnancy, other]. 
Disposition of participants will be provided in a separate data listing which will include information 
about informed consent/assent. Additional data listings will detail inclusion/exclusion criteria not met 
and protocol deviations in the Safety analysis set. 
7.4
Demographic and baseline characteristics and medical history
The following demographic and baseline characteristics (including disease characteristics) will be 
summarized on the Safety analysis set:
x
Age at screening (years)
x
Sex
x
Ethnicity
x
Race
x
Height (cm)
x
Weight (kg)
x
Body Mass Index (kg/m2)
x
Body Surface Area (m2) 
x
Type of positive T1D-related autoantibody (GADA, IA-2, mIAA, ZnT8)
x
Number of positive autoantibodies (1,2,3,4)
x
Time from T1D diagnosis to first dose of teplizumab in TN-10 Extension (weeks)
Time from T1D diagnosis to first dose of teplizumab in TN-10 Extension will be calculated as (Date 
of first dose of teplizumab in TN-10 Extension – Date of T1D diagnosis)/7. 
Demographic and baseline characteristics will also be provided in data listings for the Safety analysis 
set. This listing will include a calculation of Time from TN-10 trial treatment start to T1D diagnosis 
(months), calculated as (Date of T1D diagnosis – Date of first dose of teplizumab in TN-10 trial + 
1)/30.4375. 
Medical history will be coded using the latest version of the Medical Dictionary for Regulatory 
Authorities (MedDRA) applicable at the time of database lock. A data listing of medical history by 
participant will be provided for the Safety analysis set. 
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 12 of 21
SAP template CT
Effective: 01MAR2018
7.5
Prior and concomitant medications 
Prior and concomitant medications will be coded using the latest version of the WHODrug 
dictionary applicable at the time of database lock. Prior medications are those which start and stop 
before the first dose of study treatment. Concomitant medications are those which start before 
study treatment and continue into the study treatment period as well as medications which start 
after the first dose of study treatment is administered. 
A data listing of medications will be provided for the Safety analysis set with a designation of 
whether a medication is prior or concomitant. If there is not enough available data to make this 
designation, a medication will be assumed to be both prior and concomitant. 
7.6
Extent of exposure and compliance
Extent of exposure will be summarized for the Safety analysis set showing: 
x
Number of participants dosed with teplizumab at each visit
x
Number of doses received per participant
x
Descriptive statistics of follow up time (years) and total follow up time (person-years)
x
Cumulative total teplizumab dose (μg) in TN-10 Extension study
x
Received prior teplizumab treatment in TN-10 trial (Yes, No)
o
Time between last teplizumab exposure in TN-10 trial and first teplizumab dose in
TN-10 Extension study (months) [in subjects receiving teplizumab in TN-10 trial]
x
Cumulative total teplizumab dose (μg) in TN-10 and TN-10 Extension study 
Follow up time (years) per participant will be calculated as (Date of end of study participation – date 
of first dose of teplizumab in TN-10 Extension + 1)/365.25. 
Time between last teplizumab exposure in TN-10 trial and first teplizumab dose in TN-10 Extension 
study (months) will be calculated as (Date of first teplizumab dose in TN-10 Extension study – date 
of last dose of teplizumab in TN-10 trial)/30.4375.
Extent of exposure will also be provided in a data listing. The listing will include any relevant 
information about dose slowing, interruptions, or discontinued dosing administrations. A separate 
listing will also provide an exposure summary from TN-10 and the TN-10 Extension study for each 
TN-10 Extension participant.
7.7
Analysis of safety and tolerability
All safety analyses will be performed based on the Safety analysis set.
7.7.1 Adverse events
Adverse events will be coded using the latest version of MedDRA applicable at the time of database 
lock. 
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 13 of 21
SAP template CT
Effective: 01MAR2018
A treatment emergent adverse event (TEAE) is defined as an adverse event which starts during or 
after the first dose of teplizumab. If an adverse event occurring the same day as the first dose of 
teplizumab cannot be determined to occur before or after the dosing begins, it will be assumed to 
be treatment emergent. 
Adverse event severity is assigned according to the National Cancer Institute CTCAE v5.0. In the 
case of summaries by CTCAE grade, the highest grade experienced by the participant will be used 
for the reporting category. 
Relationship of an adverse event to study treatment will be considered as “Related” in tabular 
summaries if the options of “Possible”, “Probable”, or “Definite” are selected for the adverse event 
in the eCRF.  Options of “Unrelated” or “Unlikely” will be considered as “Not Related”. 
An adverse event is defined as an Adverse Event of Special Interest (AESI) if it meets any of the 
following criteria: 
x
All ≥Grade 3 infections (includes all opportunistic infections): viral, fungal, bacterial 
x
Acute mononucleosis-like illness (e.g., fever, pharyngitis, lymphadenopathy, clinical EBV and 
CMV infections and reactivations)
x
Malignancies including lymphomas 
x
Severe hypoglycemic episodes
x
≥ Grade 3 liver function abnormalities (AST, ALT, bilirubin), i.e., an AST or ALT value >5.0x 
ULN or a bilirubin value >3.0x ULN
x
≥ Grade 3 thrombocytopenia (platelet counts less than 50,000/μL) 
x
≥ Grade 3 neutropenia (<1000 PMN/μL on 2 consecutive evaluations performed on different 
days) 
x
≥ Grade 4 allergic/hypersensitivity reaction (anaphylaxis) 
x
≥ Grade 3 Rash
x
≥ Grade 4 cytokine-release syndrome 
x
Lymphocyte count <500/mm3 for 7 days or longer
Table 2
The Search Criteria for AESI
AESI
Search Criteria
≥ Grade 3 infections (will include all 
opportunistic infections)
SOC – ‘Infections and Infestations’; ≥ Grade 3
Acute mononucleosis-like illness (e.g., fever, 
pharyngitis, lymphadenopathy)
PT – ‘Mononucleosis syndrome’, ‘Epstein-Barr 
virus antibody positive’, ‘Epstein-Barr virus test 
positive’, ‘Epstein-Barr viremia’, 
‘Cytomegalovirus antibody positive’, 
‘Cytomegalovirus test positive’, ‘Infectious 
mononucleosis’, ‘Lymphadenopathy’,‘Epstein-
Barr virus infection’, and ‘Cytomegalovirus
infection’
Lymphomas or other malignancies
SOC –
‘Neoplasms benign, malignant and 
unspecified (incl cysts and polyps)’ and HLT –
includes ‘malignant’ or ‘lymphomas’ or ‘benign’
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 14 of 21
SAP template CT
Effective: 01MAR2018
Severe hypoglycemic episodes
PT – ‘Hypoglycaemic seizure’, ‘Hypoglycaemic 
coma’, ‘Hypoglycaemic unconsciousness’ of any 
grade; 
PT – 'Hypoglycaemia' of ≥ Grade 3
≥ Grade 3 liver function abnormalities 
(aspartate aminotransferase [AST], alanine 
aminotransferase [ALT], bilirubin) i.e., an AST 
or ALT value >5.0x upper limit of normal 
(ULN) or a bilirubin value >3.0x ULN
PT – ‘Alanine aminotransferase increased’,
‘Aspartate aminotransferase increased’,
‘Blood bilirubin increased’,
‘Liver function tests increased’,
‘Hypertransaminasemia’,
‘Transaminase elevation’,
‘Hyperbilirubinemia’; ≥ Grade 3
≥ Grade 3 thrombocytopenia (platelet counts 
less than 50,000/μL)
PT – ‘Thrombocytopenia’; ≥ Grade 3
≥ Grade 3 neutropenia (<1000 
polymorphonuclear leukocytes [PMN]/μL) on 2 
consecutive evaluations performed on different 
days
PT – ‘Neutropenia’; ≥ Grade 3
≥ Grade 4 allergic/hypersensitivity reaction, 
i.e., anaphylaxis
PT – ‘Dermatitis allergic’, ‘Drug hypersensitivity’, 
‘Anaphylactic reaction’, ‘Immune reaction’, 
‘Anaphylaxis’, 
‘Hypersensitivity’, 
‘Infusion 
related reaction’, ‘Serum sickness’; ≥ Grade 4
≥ Grade 3 rash
SOC – ‘Skin and subcutaneous tissue disorders’; 
≥ Grade 3
≥ Grade 4 cytokine-release syndrome, i.e., life-
threatening; pressor or ventilatory support 
indicated
PT – ‘Cytokine release syndrome’; ≥ Grade 4
Lymphocyte count <500 mm3 for 7 days or 
longer
PT – ‘Lymphopenia’; ≥Grade 3; at least 7 days
SOC = system organ class; PT = preferred term; HLT = high level term
Note: Nasopharyngitis, Pharyngitis, pharyngitis streptococcal should not be included in search 
criteria. 
Summary Tables
An overall summary table of treatment emergent adverse events will display the number and 
percentage of participants with at least one
x
TEAE
x
TEAE related to study treatment
x
TEAE leading to study treatment discontinuation
x
TEAE leading to study discontinuation
x
TEAE leading to death
x
TEAE by CTCAE grade
x
TEAE of special interest (AESI)
x
Serious TEAE
x
Serious TEAE related to study treatment
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 15 of 21
SAP template CT
Effective: 01MAR2018
Summary tables will be produced which display the number and percentage of participants having 
at least one of the following categories by MedDRA System Organ Class (SOC) and Preferred Term
(PT):
x
TEAE
x
TEAE related to study treatment
x
TEAE leading to study treatment discontinuation
x
TEAE leading to study discontinuation
x
Serious TEAE
x
Serious TEAE related to study treatment
Summary tables will be produced by descending frequency of MedDRA Preferred Term (PT) for the 
following categories:
x
TEAE
A summary table will be produced by AESI category (defined in Table 2) and MedDRA Preferred 
Term for the following category:
x
TEAE of special interest (AESI)
Participants with more than one TEAE in each SOC or PT will only be represented once per row in 
these summary tables by SOC and/or PT.
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 16 of 21
SAP template CT
Effective: 01MAR2018
Data Listings 
The following data listings for adverse events will be produced:
x
TEAE
x
Adverse events which are not treatment emergent
x
TEAE leading to study treatment discontinuation
x
TEAE leading to study discontinuation
x
TEAE leading to death
x
TEAE of special interest (AESI)
x
Serious TEAE
7.7.2 Laboratory safety variables
Local laboratory results for serum chemistry and hematology parameters will be converted to the 
units below and provided in a data listing. The parameters for inclusion in listings are as follows:
Serum Chemistry
Sodium (mmol/L)
Potassium (mmol/L)
Chloride (mmol/L)
CO2 (mmol/L)
Glucose (mmol/L)
Blood Urea Nitrogen (mmol/L)
Creatinine (μmol/L)
Alanine Aminotransferase (U/L)
Aspartate Aminotransferase (U/L)
Lactate Dehydrogenase (U/L)
Alkaline Phosphatase (U/L)
Total Protein (g/L)
Albumin (g/L)
Total Bilirubin (μmol/L)
Direct Bilirubin (μmol/L)
Hematology
Red Blood Cells (1012/L)
White Blood Cells (109/L)
Platelet Count (109/L)
Hemoglobin (g/L)
Hematocrit (fraction of 1)
Neutrophils (109/L)
Lymphocytes (109/L)
Monocytes (109/L)
Eosinophils (109/L)
Basophils (109/L)
The listing will also include additional details as to whether the laboratory value was considered 
abnormal or whether it was clinically significant (Yes/No).
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 17 of 21
SAP template CT
Effective: 01MAR2018
7.7.3 Vital signs and anthropomorphic measurements
Vital sign measurements including temperature (degrees Celsius), heart rate (beats/min), systolic 
blood pressure (mmHg), diastolic blood pressure (mmHg), and respiratory rate (breaths/min) will 
be provided in a data listing. Details will include the assessment (normal/abnormal) and clinical 
significance (Yes/No). 
A data listing will also be provided for all measurements of Height (cm), Weight (kg), and BSA (m2)
collected for a participant.
7.7.4 Physical examination
A data listing will be provided detailing the results of physical examinations. The listing will include 
the body system examined, the result (normal/abnormal), clinical significance (Yes/No), and any 
additional details. 
7.7.5 Pregnancy
A data listing will be provided which contains the results of pregnancy tests conducted. The listing 
will contain information about whether the test was done (if N/A due to non-childbearing potential, 
the reason for non-childbearing potential) and the pregnancy test result. 
7.7.6 Epstein-Barr virus (EBV) antibodies and cytomegalovirus (CMV) antibodies 
A data listing will contain local results for EBV IgG (negative/positive), EBV IgM (negative/positive), 
EBNA (negative/positive), CMV IgG (negative/positive), and CMV IgM (negative/positive). 
A separate data listing will contain central lab results for EBV qPCR (IU/mL) as well as CMV qPCR 
(IU/mL). 
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 18 of 21
SAP template CT
Effective: 01MAR2018
7.8
Other analyses
7.8.1 Mixed Meal Tolerance Test (MMTT)
The area under the time-versus-concentration curve (AUC) of C-peptide after a 4-hour MMTT will be 
calculated using the trapezoidal rule. To adjust the potential different durations of the MMTT test, 
C-peptide AUC will first be standardized by the duration of the MMTT test for the analysis. If the C-
peptide values at time -10 minutes and time 0 minutes are missing, the AUC will be set to missing
for the MMTT. If fewer than two measurements are available to calculate the AUC for a MMTT, the
AUC will be set to missing.
A summary table will provide descriptive statistics of the C-peptide ln(AUC+1) by visit and by prior 
treatment in the TN-10 trial. As historical data have shown the C-peptide AUC is right skewed, the 
ln(AUC+1) transformation will be applied before summarization. 
The values of the MMTT results, including both untransformed and transformed AUC, will be 
presented in a data listing. 
Graphical presentation of the ln(AUC+1) over time may be explored. 
7.8.2 HbA1c (%)
A summary table will provide descriptive statistics of HbA1c (%) by visit and by prior treatment in 
the TN-10 trial.
A data listing will be provided displaying results of local HbA1c (%) testing. 
7.8.3 Exogenous Insulin
Exogenous average daily insulin use (unit/kg/day) in the TN-10 Extension study will be presented 
by visit and prior treatment in the TN-10 trial. 
The average daily insulin use for a particular visit will be derived based on the 3 days of insulin 
recorded in the case report form prior to a visit. The body weight (kg) at the visit, if available, will 
be used in the calculation; otherwise, the average of the closest prior and post-visit weights will be 
used.
Information on exogenous insulin will be presented in a data listing. The listing will include the 
nominal day reported (3 days prior to visit, 2 days prior to visit, 1 day prior to visit) as well as the 
insulin name and dosing.
7.8.4 Insulin Discontinuation Criteria
TN-10 Extension participants meeting insulin discontinuation criteria (defined as HbA1c ≤6.5% and 
average daily insulin use ≤0.25 unit/kg/day) at each visit will be summarized, by prior TN-10 trial 
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 19 of 21
SAP template CT
Effective: 01MAR2018
treatment and overall. Only participants who have available HbA1c and insulin data at the relevant 
visit will be included in the summary. 
7.8.5 Severe Hypoglycemic Episodes
Severe hypoglycemic episodes following the AESI definition in Table 2 will be provided in a 
data listing. 
7.8.6 Pharmacokinetics and Immunogenicity
Blood samples will be obtained on Days 1, 4, 9, 12 (before study drug infusion) and on Days 28, 
182, and 364 to measure teplizumab trough levels, anti-drug antibodies, and neutralizing antibodies. 
Teplizumab concentrations will be provided in a data listing on the PK analysis set. 
The titers of anti-drug antibodies and presence of neutralizing antibodies will be measured in 
samples collected. Information including antibody titer will be provided in a data listing on the 
Immunogenicity analysis set. 
7.8.7 Mechanistic Assessments
Details of the mechanistic assessments, including the secondary endpoint of assessing frequency of 
CD8+ TIGIT+ KLRG1+ T cells, will be provided in a separate mechanistic analysis plan. 
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 20 of 21
SAP template CT
Effective: 01MAR2018
7.9
Interim analysis
An interim analysis is not planned.
7.10 Changes in the statistical plans from those presented in the study 
protocol (if applicable)
x
The protocol specifies the use of both an ITT and Safety analysis set.  The SAP defines only 
the Safety analysis set as those participants who receive at least one dose of study drug. 
x
The frequency of CD8+ TIGIT+ KLRG1+ T cells will be part of a separate mechanistic analysis 
plan. 
x
The protocol specifies that comparisons will be made in C-peptide with historical controls. 
Due to the small number of patients enrolled in the TN-10 Extension study, these 
comparisons will not be performed as part of this SAP. 
x
The definition of adverse event of special interest (AESI) in the SAP is different from the 
study protocol and aligns with the AESI definition as agreed upon with FDA for the Integrated 
Summary of Safety (ISS) for the at-risk BLA approved in November 2022. 
7.11 Execution of statistical analyses
Statistical analysis will be performed by IQVIA Biotech under the supervision of Provention Bio, Inc.
and Sanofi.
8
HARDWARE AND SOFTWARE
Statistical analysis, tables, figures, and participant data listings will be performed with SAS® for 
Windows version 9.4 or higher (SAS Institute Inc., Cary, NC, USA).
9
REFERENCES
1)
SAS, Institute Inc., Cary, NC, USA.
10 APPENDICES
None
11 DOCUMENT HISTORY
Version 
number
Version 
date
Author
Comments
0.1
17MAR2021
N/A – First version
VV-CLIN-0674120 1.0


  PRV-031-002 Statistical Analysis Plan v1.0
TEMP-OP-401-A01.01
Confidential
Page 21 of 21
SAP template CT
Effective: 01MAR2018
0.2
24MAY2023
Updated to clarify most presentations 
would be data listings due to expected 
enrolment.
1.0
25OCT2023
Updated per PRVB team review
1.0
18JAN2024
Finalization of SAP text per 2nd team 
review
1.0
21FEB2024
Minor editorial changes prior to signature 
of V1.0.
VV-CLIN-0674120 1.0